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 The American Heart Association (AHA) estimates that at least one American will 
die from a coronary event every minute, costing over $150 billion in 2008 alone.  
Regenerating the myocardium of patients that survive the initial infarction has proven to 
be an elusive goal.  A variety of factors – including the loss of contractile cells, 
inflammatory response following infarction, cardiac hypertrophy, and lack of suitable 
cues for progenitor cells – causes fibrosis in the heart and loss of cardiac function.  This 
dissertation examines three drug delivery strategies aimed at improving conditions for 
cardiac regeneration: polyketal microspheres as non-inflammatory drug delivery vehicles; 
surface functionalization of microparticles with nitrilotriacetic acid-nickel (NTA-Ni) for 
non-covalent tethering of proteins; and using Hoechst-inspired ligands for targeting 
extracellular DNA in necrotic tissue. 
 The non-acidic degradation products of poly(cyclohexane-1,4-diyl acetone 
dimethylene ketal) (PCADK) make it a prime candidate for treating inflammatory 
disease.  We tested the in vitro and in vitro biocompatibility of the polymer and found 
that it did not significantly recruit or activate inflammatory cells and had comparable pro-
inflammatory cytokine levels compared to saline injection.  We formulated 
microparticles containing SB239063, a p38 mitogen associated protein kinase (MAPK) 
inhibitor, and found that we were able to improve cardiac function in a rat model of 
myocardial infarction with PCADK microparticles, but not with size- and loading-
matched poly(lactic-co-glycolic acid) (PLGA) microparticles suggesting that the polymer 
chemistry played a role in preventing fibrosis. 
xix 
 
 NTA-Ni complexes are traditionally used in immobilized metal affinity 
chromatography (IMAC) purification of Histidine-tagged recombinant proteins.  The 
surface of polymer microparticles was functionalized with NTA-Ni complexes, which 
can be used as a non-covalent tethering mechanism for therapeutic proteins and targeting 
ligands.  Utilizing immobilized metal chelates prevents protein denaturation by 
eliminating exposure of proteins to organic solvent and maintains high loading efficiency, 
even when using dilute protein solutions.  Bioactive growth factors can be released from 
the microparticles and modest cell surface targeting was achieved using vascular 
endothelial growth factor (VEGF) and vascular-endothelial cadherin (VE-Cadherin) as 
model protein systems. 
 Traditional drug targeting schemes rely on antibody-antigen interactions.  This 
strategy inherently limits the lower bound of the size, and therefore diffusivity, of a drug 
delivery vehicle.  Furthermore, this strategy relies on identifying protein antigens with 
tissue-specific expression or upregulation.  Instead, studies focused on examining the 
potential for targeting another biomarker for tissue damage post-myocardial infarction, 
extracellular deoxyribonucleic acid (DNA) generated in necrotic cell death.  Using 
Hoechst as an inspiration, a variety of conjugates were synthesized that can be used for 










 Heart disease is a growing problem across the world, resulting in enormous 
patient and financial burdens.  Lifestyle changes that combat obesity, such as increasing 
physical activity and maintaining a healthy diet, are among the most effective treatments.  
However, increasingly sedentary lifestyles and poor patient compliance have slowed 
progress in combating cardiovascular disease (CVD).  Furthermore, treating patients that 
already show signs of CVD will rely on drug discovery and development of new 
technologies to effectively deliver these compounds.   
1.1 Motivation 
 The AHA estimated that over a million Americans suffered a myocardial 
infarction (MI) in 2010 [1].  Improved therapies such as percutaneous coronary 
intervention and antithrombotic drugs have reduced the mortality rate of MI.  While it is 
increasingly likely that patients survive the initial infarction, progressive cardiac 
dysfunction remains an issue due to loss of contractile heart muscle and reduced cardiac 
output.  For patients with severe cardiac dysfunction, the only definitive cure is heart 
transplantation.  While this treatment can extend a patient’s life by years, there are 
inherent issues, including donor availability and requisite immunosuppression.  
Additional strategies are needed to rescue and regenerate the patient’s own myocardium. 
 The loss of cardiac function stems from the inadequate healing response of heart 
tissue post-MI.  The body replaces the damaged heart tissue by hypertrophy of surviving 
cardiac myocytes and generation of a non-contractile scar, which leads to adverse cardiac 
remodeling in response to the changes in cardiac load and eventual heart failure.  Old 
dogma concluded that the heart was a terminally differentiated organ with no 
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regenerative capacity.  However, recent findings have overturned this and have identified 
cells and cues that are central to the regenerative response [2-4].  The biology behind 
achieving cardiac regeneration is a rapidly evolving area of research with potential 
treatments – ranging from cell therapy [5] to soluble factors [4] – being explored 
worldwide.  Though studies show promise in some instances, one common shortcoming 
is the lack of suitable delivery vehicles for the treatment, which can drastically improve 
the efficacy of existing therapies.  This dissertation focuses on the design of new drug 
delivery vehicles given the constraints of the post-MI environment. 
1.2 Research Objectives 
  Delivering regenerative cues to the heart post-MI requires strict spatiotemporal 
control in order to be effective.  Given the phases of cardiac dysfunction, discussed in 
Chapter 2, delivering a particular drug at the wrong time or location can have no effect or 
in the worst case scenario, produce deleterious side effects.  Drug delivery vehicles can 
give researchers spatiotemporal control over the drug concentration in a tissue and can 
thus boost a therapeutic’s efficacy.  The main objective of this project was to design and 
synthesize candidate drug delivery vehicles that are appropriate for treating cardiac 
dysfunction. 
 Degradable polymers are routinely used in a variety of drug delivery systems [6].  
A therapeutic of interest can be encapsulated in a polymer matrix, which serves as a 
depot for sustained delivery.  The polymer matrix can then be fabricated into a number of 
forms, including microspheres, for implantation into the body.  As the polymer degrades, 
the therapeutic is released into the surrounding tissue thereby maintaining a 
therapeutically relevant concentration of the drug.  The most commonly used degradable 
polymer family, polyesters, are based on a hydrolyzable linkage that generates acidic 
degradation products.  While suitable for certain applications, these acidic products have 
the potential to produce or exacerbate inflammation [7, 8].  The polyketal class of 
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degradable polymer is based on a linkage that produces neutral degradation products 
(acetone and a diol).  These products do not affect pH and may have beneficial properties 
for treating inflammatory diseases.  The first specific aim examines the biocompatibility 
of PCADK microspheres in the heart.  Furthermore, a p38 MAPK inhibitor was 
encapsulated in PCADK microspheres and tested in a rat model of MI. 
 Synthetic, hydrophobic polymers are ideal for encapsulating traditional small 
molecule pharmaceuticals.  Traditional drugs are generally hydrophobic and have high 
solubility in polymer matrices, allowing high loading efficiencies and predictable release 
kinetics.   However, therapeutic proteins are becoming increasingly important for treating 
patients and have different physicochemical properties.  Protein activity relies strongly on 
the secondary and tertiary structures of the molecule, which are largely dictated by 
hydrophobic/hydrophilic interactions.  As a result, there is a high risk of protein 
denaturation when proteins are removed from aqueous solutions and come in contact with 
organic solvents that are typically used to process synthetic polymers.  As a result, 
complex processing techniques are required to microencapsulate proteins into polymer 
matrices in high, bioactive amounts.  The second specific aim will examine techniques to 
non-covalently tether proteins to the surface of microparticles using simple immobilized 
metal affinity strategies. 
 Another major focus in the development of drug delivery vehicles is the ability to 
target therapeutics to a particular tissue.  Targeted therapeutics can be delivered 
systemically at lower doses, and due to enrichment at the organ of interest, beneficial 
concentrations of a drug can be maintained.  This is particularly advantageous where 
access to the organ of interest is limited, such as the heart.  Tissues have been 
traditionally targeted by identifying particular proteins that are highly expressed or 
upregulated in the diseased state.  These proteins then serve as antigens for high affinity 
interactions with antibody-conjugated drug delivery vehicles.  Antibody-based systems 
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are typically larger (<50 nm in diameter) and have trouble diffusing far from capillaries.  
Furthermore, identification of candidate target proteins can be difficult for particular 
diseases where organ specific expression is not prevalent.  The final specific aim will 
investigate the feasibility of using extracellular DNA generated during necrosis as a 
targeting platform.  Small molecule dyes for DNA are routinely used for quantification 
and histology in lab and high affinity interactions.  Molecules inspired by these DNA 
binding dyes can potentially aid in reducing the size of the drug delivery vehicle while 
achieving similar levels of targeting.  The final specific aim will examine using Hoechst 
conjugates to bind extracellular DNA in the necrotic core of the infarct as a mechanism to 
target therapeutics to the heart. 
1.3 Specific Aims 
 The central hypothesis of this dissertation asserts that judicious design of drug 
delivery vehicles can improve the efficacy of therapeutics in the failing heart.  The 
underlying chemistry must be well suited to overcome the specific challenges presented 
by the environment of the myocardium after infarction.  This dissertation focuses on the 
evaluation of three novel drug delivery strategies for treating cardiac dysfunction. 
Specific Aim 1: Evaluate the biocompatibility and efficacy of PCADK microspheres for 
delivering anti-inflammatory drugs 
 We hypothesized that PCADK microparticles can more effectively deliver anti-
inflammatory drugs to the heart compared to commonly used polyesters due to the fact 
that neutral degradation products of polyketals and improved biocompatibility.  In this 
study, the response to PCADK microspheres was measured and the ability of PCADK 
formulations to release anti-inflammatory drugs in the heart after MI was assessed.   
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Specific Aim 2: Development of metal-affinity based protein delivery and targeting for 
microspheres.   
 We hypothesized that non-covalent tethering of histidine-tagged (His-tag) 
proteins can be achieved by incorporating NTA-Ni complexes on the surface of 
microparticles.  This functional handle allows us to use the surface of microparticles to 
immobilize therapeutic proteins as well as targeting ligands.  More importantly, this 
strategy eliminates exposure to organic solvent thus improving bioactivity and loss of 
protein.   
Specific Aim 3: Assess the feasibility of targeting the infarct via extracellular DNA 
released by necrotic cells using small molecule conjugates 
 We hypothesized that the DNA-binding dye Hoechst 33258 (Hoechst) can be 
used to target necrotic regions of the heart following intravenous injection.  DNA does 
not usually persist in the extracellular space in healthy individuals.  However, 
extracellular DNA is connected to some pathological conditions, including necrotic cell 
death, which is prevalent acutely following MI.  Hoechst has long been used as a 
fluorescent marker of DNA in histological and cytological applications due to its high 
binding affinity for DNA.  A variety of Hoechst-conjugates have been synthesized in 
order to assess the presence of extracellular DNA and potential for targeting therapeutic 





2.1 Myocardial infarction and the progression of cardiac dysfunction 
 Myocardial infarction (MI), or more colloquially known as “heart attack,” is 
loosely defined as loss of blood flow to a region of the heart, and subsequent death of 
cardiac tissue.  Treatments developed over the past thirty years, such as percutaneous 
transluminal coronary intervention and antithrombotic drugs, have made survival of the 
initial obstruction of a coronary artery more likely.  However, even after reperfusion of 
the heart, nearly one in ten will die due to lethal reperfusion injury and nearly one in four 
will suffer from cardiac dysfunction [9].  The heart does not have a sufficient, 
endogenous healing response following infarction and a number of factors converge to 
prevent regeneration. 
Temporal aspects of cardiac dysfunction and the role of inflammation 
 The onset of myocardial infarction occurs with the occlusion of a coronary artery.  
Blockage of a major artery in the heart halts flow of oxygen and other nutrients to 
downstream tissue and causes the accumulation of metabolic waste.  The downstream 
myocardium rapidly depletes available adenosine triphosphate (ATP), and if flow is not 
restored, cardiac myocytes begin to die through a number of pathways.  In clinical 
settings, one of the key goals for treating patients expressing symptoms of MI is 
minimizing the amount of time to administration of thrombolytic drugs or angioplasty.  
These treatments aim to restore blood flow to the heart through biochemical or 
mechanical routes.  Rapid reperfusion is crucial, as the amount of cardiac tissue initially 
lost is dependent on the duration of occlusion. 
7 
 
 While reperfusion is important for salvaging the heart, restoration of flow is a 
double-edged sword; decreasing the duration of occlusion decreases infarct size, but 
reperfusion can cause additional cell death through several mechanisms [10-15].  
Reoxygenation of cardiac tissue can increase oxidative stress due to the generation of 
reactive oxygen species (ROS).  This can reduce the bioavailability of nitric oxide 
radicals, which has downstream effects of promoting neutrophil accumulation and 
reduced superoxide inhibition.  Oxidative stress is further compounded by the recruitment 
of inflammatory cells into the infarct, which is effectively treated as a wound [16].     
 
 
Figure 2.1. Inflammatory phases in the heart post-MI.  Infarct healing follows a classical wound healing 
trajectory that is also seen in responses to implanted biomaterials.  Inflammatory cells are recruited to the 
infarct at different times following MI.  Neutrophils are the primary early responders and persist hours to 
days following injury.  Macrophages respond with a slight delay but persist longer than neutrophils.  
Macrophages and neutrophils are responsible for clearing the infarction of dead cells and other debris.  By 
three to seven days, voids left by dead cardiac myocytes are filled by granulation tissue, which is composed 
of neovasculature, fibroblasts, and macrophages.  Myofibroblasts respond days to weeks days following 
injury and begin to synthesize extracellular matrix (i.e. collagen) in response to the loss of mechanical 
integrity in the infarct.  The granulation tissue eventually matures into a collagenous scar.  Adapted from 
Frangogiannis, Antioxid. Redox Signal. (2006) [17]. 
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 The role of inflammation in cardiac dysfunction has been well characterized in 
experimental models of MI.  It is generally believed that the cell death during ischemia 
activates the complement cascade, which triggers additional components of the 
inflammatory response [18].  Amongst other cytokines, tumor necrosis factor alpha 
(TNF-α) has been implicated in the response of heart tissue following acute MI [19-23].  
TNF-α may set off the cytokine cascade that leads to apoptosis of cardiac myocytes and 
increase in ROS in the myocardium.  The generation of ROS and amplification of the 
inflammatory response have feed forward effects that destroy viable cardiac myocytes 
[11, 24], further compromising cardiac function.  Studies that systematically reduced 
inflammatory cytokines or specific ROS have had success in small animal models but 
human clinical trials have seen mixed results [25, 26]. 
 One of the central radical oxidants involved in cardiac dysfunction is superoxide.  
Superoxide is typically generated by neutrophils and other phagocytic cells by β-
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, but can also be 
produced by cardiac myocytes, fibroblasts, and endothelial cells in the heart under certain 
stimuli (e.g. angiotensin II, TNF-α).  Under healthy conditions, this production of 
superoxide is balanced by the scavenging properties of superoxide dismutase (SOD), 
which converts superoxide to hydrogen peroxide.  Hydrogen peroxide is broken down 
further into water and oxygen by catalase and glutathione peroxidase.  However, studies 
have shown that SOD expression is decreased following MI [27].  This can cause a 
pathological condition where increased superoxide reacts to form other harmful radicals 
such as peroxynitrite and hydroxy radicals (dotted line pathways, Figure 2.2).  Various 
studies have shown that increasing levels of SOD following MI has beneficial effects on 
cardiac functions [28, 29], but delivery remains difficult due to the short circulation half 




Figure 2.2. Reactive oxygen species pathways in heart failure. Superoxide plays a central role in the 
generation of free radicals.  Superoxide is produced by inflammatory cells or cardiac cells that have been 
stimulated by a variety of different factors.  Superoxide can then react with other compounds to produce 
additional radical oxidants such as peroxynitrite or the hydroxy radical.  The antioxidant enzymes 
superoxide dismutase, catalase, and glutathione-peroxidase are crucial in regulating the redox environment 
in healthy tissue.  (GSH-PO – glutathione peroxidase, SOD – superoxide dismutase, PMN – 
polymorphonuclear leukocytes, Ang II – angiotensin II, TNF-α – tumor necrosis factor alpha, TGF-β – 
transforming growth factor beta, NAD(P)H – reduced nicotineamide adenine dinucleotide phosphate, CM – 
cardiac myocyte, Fb – fibroblast, EC – endothelial cell) Adapted from Sorescu and Griendling, CHF (2002) 
[24]. 
Spatial organization of the infarct and modes of cell death 
 Cell death can occur through a number of different pathways, depending on the 
stimuli that initiate cell death as well as the amount of ATP available to the cell.  Most 
cell death in the healthy human body occurs through programmed cell death or apoptosis.  
This is a highly organized death pathway activated by a variety of well defined cell 
signaling events. The general hallmarks of apoptosis involve DNA laddering, controlled 
recycling of cellular components, and eventual degeneration into apoptotic bodies (with 
intact cell membranes) that are cleared by inflammatory cells.  On the other end of the 
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spectrum is necrosis, an energy independent process.  Necrosis is marked by disruption of 
cell membrane integrity, which leads to the leakage of intracellular components into the 
interstitial spaces between cells.  These fragments can recruit large numbers of 
inflammatory cells, which eventually clear necrotic debris.  Autophagy lies between 
apoptosis and necrosis in the spectrum of cell death and is characterized by fusion of 
organelles with lysosomes and enlargement of membrane bound vesicles.  This process 
frees nutrients for other cellular processes.  The prevalence of autophagy, as well as 
effect on cardiac dysfunction, is still under debate [31].   
 In general, the pattern of cell death in the infarct corresponds to the gradient of 
ATP and oxygen depletion (Figure 2.3).  As distance increases from the arterial 
occlusion, more ATP and oxygen are available to cells due to collateral circulation.  The 
area directly downstream of the occlusion experiences anoxic conditions, resulting in a 
necrotic core.  In humans, these necrotic lesions are macroscopic entities that can be seen 
by the unaided eye [32].  The infarct core is generally considered to be unsalvageable.  
The border zone contains significant numbers of cardiac myocytes that have undergone 
cellular damage, but are still viable immediately after infarction.  However, due to the 
hostile microenvironment in the infarct, many of these cells undergo apoptotic cell death.  
Autophagy may also play a significant role in cell death in the border zone, but this has 
yet to be fully determined.  Remote myocardium that is not directly downstream of the 
occlusion does not suffer from much cell death acutely post-infarction.  However, soluble 
factors and other cues may cause delayed apoptotic cell death concurrent with the 




Figure 2.3.  Types of cell death involved in myocardial infarction.  The extent of ATP depletion 
generally dictates the cell death pathway, and therefore, the regions of cell death are typically defined by 
the distance from the occlusion.  The most severe area of ATP depletion occurs at the core of the infarct 
and primarily drives necrotic cell death in the acute stage.  As distance increases from the core into the 
border zone, apoptosis overtakes necrosis as the primary mode of cell death.  While still controversial, it is 
believed that a small level of autophagy may occur in this region.  Distal areas of the myocardium are 
generally not affected acutely by the infarction (i.e. do not experience loss of oxygenation/depletion of 
ATP), but can experience delayed cell death, primarily through apoptotic pathways, due to soluble 
signaling factors.  Adapted from Mani, Heart Fail Rev (2008) [31]. 
 
2.2 Cardiac drug delivery vehicles 
 Systemic, intravenous, or intracoronary delivery of small molecules and proteins 
remain popular forms of drug delivery for treating MI due to minimal invasiveness.  
These delivery methods require frequent dosing to achieve therapeutic concentrations in 
the infarct zone for significant periods of time.  This pulsatile concentration profile and 
high systemic concentration greatly increases the chances for potential side effects and 
toxicity.  More localized delivery of therapeutics may be achieved by specialized surgical 
tools for direct intramyocardial injection [33].  This approach is effective for cell therapy, 
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where the “therapeutic” ultimately engrafts in the site of injection.  However, for 
pharmaceutical interventions (i.e. soluble drugs) localized injections are quickly washed 
into bloodstream, both diluting the therapeutic and negating any local delivery effects.  
Two alternative delivery strategies that circumvent these issues are systemically delivered 
targeted drug delivery vehicles and locally delivered sustained release formulations.   
Controlled release formulations 
 A variety of diseases have been treated using controlled release systems.  The 
general principal behind controlled release is that a reservoir of sequestered drug is 
implanted in the body.  Through a combination of diffusion, degradation, or more 
sophisticated release mechanisms, the drug is slowly administered to the affected area 
[34-36].  This gradual release of drug bypasses the need for repeated dosing and tailoring 
the rate of release versus the rate of drug metabolism can achieve a desired therapeutic 
concentration.  Degradable polymers are often used in controlled release applications. 
 
Figure 2.4.  Degradable polymers used in drug delivery.  Polyesters are FDA-approved for a number of 
medical applications.  PLGA is used in commercial formulations as well as in other medical devices such 
as degradable sutures and screws.  Polyanhydrides are another class of FDA-approved degradable polymer 
used in drug delivery.  Polyanhydrides have rapid hydrolysis kinetics, which give them surface eroding 
properties.  Polyketals are a new class of degradable polymers hypothesized to have improved tissue 




 Biodegradable, hydrophobic polymers have been widely used in sustained release 
formulations both in the clinic and in research laboratories.  Synthetic polymers are often 
better characterized than naturally derived materials and can survive a variety of 
processing techniques.  The most common class of biodegradable polymers used in 
medicine is polyesters, such as PLGA.  These polymers rely on the water-cleavable ester 
linkage and degrade into low molecular weight carboxylic acids which can be 
metabolized or cleared by the body and are among the few biodegradable polymers 
approved by the Food and Drug Administration (FDA) in the United States.  Following 
the approval of PLGA as a suture material by the FDA, researchers have explored using 
biodegradable polymer microspheres as controlled release vehicles for drugs.  Several 
microsphere formulations, including Lupron Depot (Abbott Labs) and Zoladex (Astra 
Zeneca), are currently on the market for the treatment of prostate cancer, breast cancer, 
endometriosis, and other disorders.  These formulations rely on the principle of controlled 
release of an encapsulated drug from a biodegradable polymer matrix.  Release of the 
drug occurs through a combination of hydrolysis of the polymer matrix and diffusion of 
the drug out of the microsphere.  The net result is that therapeutic concentrations of the 
drug can be maintained for a longer time with fewer administrations.  This concept is 
particularly important for drugs with short circulation half lives or for those that are 
potentially toxic at high concentrations.  These formulations have the benefit of not 
relying on patient compliance for maintaining therapeutic levels of the drug in the 
bloodstream.  
 Polyanhydrides, another FDA-approved class of biodegradable polymers, are used 
in the formulation of Gliadel (Eisai) for the treatment of brain tumors.  These polymers 
degrade into acidic products by base-catalyzed hydrolysis.  The role of these acids in 
inciting an inflammatory response has been debated in the literature [19, 46-51].  
Delivery vehicles fabricated for these polymers may not be suitable for use in 
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inflammatory diseases where the vehicle itself may exacerbate the condition, suggesting 
that new polymer chemistries need to be explored for treating inflammatory disease. 
 Reports of cardiac-specific drug delivery vehicles are scarce.  While not widely 
used for drug delivery directly to the myocardium, PLGA has been used for other 
cardiovascular applications such as stent coating [36, 37] and cardiac tissue engineering 
[38].  PLGA and the related polymer poly(glycolic acid) has been widely used in tissue 
engineering, particularly as a controlled release platform to temporally control growth 
factor release for neovascularization of constructs [39].  There has been one report of a 
potential myocardial application of PLGA to deliver heat shock protein-27 in a controlled 
manner [40].  In this study, the treatment was performed on cultured cardiomyocytes 
only, though it was able to rescue these cells from apoptosis.   
 
 
Figure 2.5. Polyketals degrade into neutral degradation products.  Polyketals are characterized by the 
acid catalyzed ketal linkage (-O-C-O-), which degrades into a diol and acetone.  This is unique amongst 
other degradable polymer systems since these byproducts do not affect pH.  
 
 Our laboratory has focused on the use of a new class of biodegradable polymers 
called polyketals [41].  Polyketal technology is central for Specific Aim 1 and is 
discussed in depth in Chapter 3.  Polymers based on the ketal linkage provide key 
advantages over the more widely used polyesters.  The ketal linkage is an acid-sensitive, 
hydrolyzable bond that degrades to produce acetone and a diol (Figure 2.5) and can be 
tuned to degrade over time spans ranging from days to months [42, 43].  The two main 
advantages with using polyketals over more established degradable polymers lies in 
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biocompatibility of the degradation products.  Polyketals have the unique property of 
degrading into neutral compounds rather than acidic byproducts.  As a result, degradation 
of polyketals in vivo does not affect the local pH in the surrounding tissue, which may 
happen with polyester degradation [44-47].  This is a potential advantage when treating 
diseases where inflammation plays a large role and specific examples are given in 
Chapters 3 and 6. 
Protein Delivery Systems 
  Hydrophobic, biodegradable polymers, such as PLGA and polyketals, have been 
widely used to deliver drugs to diseased tissues.  There is currently great interest in using 
these polymers for the delivery of proteins, however protein-based therapeutics present 
unique challenges for drug delivery vehicle design.  Microencapsulation of traditional 
pharmaceuticals (small molecules) has been straightforward in hydrophobic 
biodegradable polymers due to good drug solubility in organic solvents and stability over 
a wide range of temperatures.  However, the secondary and tertiary structures of proteins 
strongly dictate bioactivity and are sensitive to processing conditions such as temperature 
and exposure to organic solvent.  These properties have made it more difficult to 
microencapsulate proteins and limited the widespread use of protein delivery via 
microparticles . 
 A common procedure used to encapsulate proteins in hydrophobic polymer 
microparticle systems employs a double emulsion, solvent evaporation procedure [37-
40].  In this process, the protein is typically dissolved at a high concentration in aqueous 
medium and emulsified into an oil phase that includes the polymer matrix.  This first 
emulsion is then homogenized in a second water phase, forming the second emulsion that 
gives rise to the microparticle shape.  Polymers such as PLGA and PCADK, have been 
used successfully to deliver proteins in vivo, but the techniques used to encapsulate the 
proteins are not optimal.  During the drying process, the protein is exposed to organic 
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solvent, which frequently damages its structure/activity.  The protein can also diffuse out 
of the microparticle while organic solvent evaporates, reducing encapsulation efficiency.  
Approaches such as solid/oil/water emulsions have attempted to address these issues, but 
they require additional processing steps and use hydrophilic polymer carriers, such as 
poly(ethylene glycol) (PEG) and sodium alginate, to protect proteins from denaturation 
[41, 42].   
 Another broad class of drug delivery particles is based on naturally derived 
hydrogels. Extracellular matrix proteins – such as collagen, gelatin, and fibrin – have 
been used as matrices for sustained release of therapeutic compounds, particularly 
hydrophilic compounds.  These materials are often supplemented with synthetic 
hydrogels, such as poly(ethylene glycol), in order to improve mechanical properties or 
impart specific functionalities [43, 44].  However, these materials are typically delivered 
as an injectable hydrogel or tissue engineered patch for cell delivery or tissue 
engineering.  Hydrogels have been formulated as microparticle drug delivery vehicles.  
Gelatin microparticles have been used to encapsulate angiogenic and anti-fibrotic factors.  
These include plasmid DNA, proteins such as basic fibroblast growth factor, and 
chemical agonists [45-47].  While potentially biocompatible, there are concerns regarding 
the ability to control degradation profiles, especially with potential upregulation of 
gelatinases and other proteases following MI [48].   
 In an effort to avoid denaturation due to organic solvents, alternative protein 
delivery systems have focused on hydrophilic materials to achieve sustained delivery of 
proteins.  Most of these approaches use crosslinked biologically derived polymers, such a 
gelatin or alginate, or synthetic polymers, such as PEG, to form a matrix around 
polymers, thus reducing diffusivity.  A variety of crosslinking strategies, including 
covalent [49-51], ionic/electrostatic [52], and mechanical [53] strategies have been used 
to form drug delivery vehicles with these polymers.   
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 Immobilized metal affinity chromatography (IMAC) techniques have been used 
to purify recombinant proteins for over thirty years and are well suited for protein 
delivery since they rely on non-covalent, reversible interactions with proteins [54, 55].  
IMAC works by immobilizing chelating chemical groups on a substrate, which in turn 






).  The use of nitrilotriacetic 
acid (NTA) for IMAC was reported in 1987 by Hochuli, et al. and has become one of the 
more widely used chemistry in commercially available products [55].  The bond strength 
for these types of interactions have been estimated to be in the 200-400 pN range by 
using single molecule AFM studies [56].  Studies have been performed varying the 
number of histidine residues on the protein as well as the valency of NTA on the capture 
substrate in order to tune dissociation constants and thus provide a pathway for changing 
release kinetics [57, 58].  This metal complex binds sequential histidine residues on 
proteins and interacts with a high affinity ranging from 13 mM to 1.2 nM depending on 
NTA valency and other factors [59, 60]. 
 Recently, NTA chemistry has been employed for a variety of new applications 
outside chromatography.  Polystyrene microparticles have been modified with NTA for 
flow cytometric analysis of proteins [61].  NTA has also been used in lipid bilayers to 
examine protein interactions; 1,2-dioleoyl-sn-glycero-3- [N (5-amino-1-carboxypentyl) 
iminodiacetic acid] succinyl (DOGS-NTA), a lipid conjugate of NTA, was used to create 
two dimensional protein crystals and study protein-protein interactions on supported lipid 
bilayers [62-64].  Despite these new applications, NTA has seen limited use for drug 
delivery purposes.  Researchers have functionalized liposomes with DOGS-NTA for 
capturing and presenting His-tagged proteins [65-68].  In addition, poly(ethylene glycol) 
(PEG) hydrogels have been functionalized with NTA in order to retard the release rates 
of proteins encapsulated in the hydrogels [43, 69, 70].  Similar affinity-based strategies 
have been attempted using heparin interactions.  Previous work with PLGA 
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microparticles and other materials have functionalized surfaces with heparin [46, 71].  
This approach relies on heparin binding domains found on many growth factors.  The 
affinity between heparin and various growth factors allows for local retention and 
sustained delivery, but the heparin binding domain is significantly larger than the His-tag 
and may not be as useful in vivo due to numerous proteins that naturally contain these 
domains.  
Targeted Drug Delivery Vehicles 
 One goal in drug delivery is the targeted delivery of therapeutics.  Ideally, one 
would be able to administer a formulation to a patient either orally or through intravenous 
injection and have the drug home to a specific tissue or region of the body.  This strategy 
reduces the risk of systemic effects of a drug as well as lowers the necessary dose of the 
drug.  This approach has been pursued in the field of cancer treatment due to the 
toxicity/systemic effects of the associated drugs and attractive targeting characteristics of 
tumors.  The traditional approach for targeted drug delivery is to identify proteins that are 
either unique to a particular disease or specifically upregulated in a given condition [72, 
73].  Cancer is an excellent model for targeted drug delivery since tumors generally have 
“leaky” vasculature as well as very specific cell surface markers [73].  Leaky vasculature 
permits enhanced permeability and retention (EPR) of delivery vehicles (typically nano- 
or micro-particles) into the tissue of interest.  The actual targeting agents employed can 
vary from study to study, but the many studies use antibodies specific to the protein target 
of interest [65, 74, 75].   
 Targeting the myocardium has primarily focused on using liposomal and 
antibody-based approaches.  Antibodies directed against intracellular proteins exposed 
following infarction and inflammatory proteins that are upregulated following MI have 
been the focus of infarct-specific delivery [76-78].  However, some research suggests that 
the infarcted heart inherently has an EPR property similar to that seen in tumors which 
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may passively enhance accumulation of nanoparticles in the infarct [79].  While these 
liposomal formulations require modifications for serum stability [80], they offer the 
advantages of excellent size control at the submicron scale and the unique potential to 
“plug and seal” membranes [81].  This phenomenon was hypothesized by a group that 
used liposomal formulations to deliver adenosine triphosphate (ATP) [82] to rabbit 
models of MI, which reduced the volume of at-risk myocardium as measured by nitroblue 
tetrazolium.  Other groups have utilized the mechano-acoustic properties of liposomes in 
order to achieve on-demand release of encapsulated therapeutics.  Liposomes can be 
acoustically disrupted by ultrasound, a common imaging modality for cardiovascular 
applications, resulting in localized delivery [83].  A variety of compounds have been 
delivered to the heart including gene therapy constructs for VEGF, ATP, and coenzyme 
Q10 [83-86]. 
2.3 Necrosis, extracellular DNA, and DNA-binding compounds 
 As described previously, necrosis plays a central role in myocardial infarction and 
the progression of cardiac dysfunction.  MI represents one of the few pathological 





 cells die naturally every day.  This accounts for 1-10 grams of DNA being 
cleared or recycled by the body.  Under most circumstances, the cell death progresses 
through apoptosis and the DNA is laddered into180n base pair fragments by 
deoxyribonuclease (DNase) II.  While there are reports of apoptotic cells shedding DNA, 
most is contained within the apoptotic body and cleared by inflammatory cells [87].  
DNA produced by necrosis, by comparison, is cleaved by DNase I into 20-80 kilobase 
pair fragments and the entire genome is released into the interstitial space or circulation 
due to loss of membrane integrity [88].  Experimental measurements done in rats suggest 
that DNA circulating in the blood is cleared rapidly.  Hisazumi, et al. injected 
radiolabeled DNA into rats and found that less than 90% of the DNA was still present in 
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the plasma after 10 minutes [89].  Nearly 99% was cleared in thirty minutes.  Most of the 
radiolabel (60%) was detected in the liver, suggesting hepatic clearance pathways. 
 Certain pathological conditions can increase the occurrence of extracellular DNA.  
One prime example is cancer.  Large tumor masses often develop necrotic cores, as the 
rate of cancerous cell division outpaces development of blood vessels to perfuse the 
center of the tumor.  There have also been reports of increased circulating DNA in the 
blood of patients with metastatic tumors [90], but the sources remain unclear.  Other 
conditions that have been documented to increase levels of extracellular DNA include 
traumatic injuries [91], cystic fibrosis [92], lupus [93], bacterial biofilms [94], and 
pregnancy [95]. 
 Hoechst compounds have a long history of being used as fluorescent markers of 
DNA for use in histology and flow cytometry due to its large increase in fluorescence 
upon binding to nucleic acids [96-98].  Hoechst dyes are minor grove binding agents that 
have a high affinity for regions of DNA rich in AT-sequences [99, 100].  Due to their 
unique minor groove binding properties, some studies have been conducted using 
Hoechst derivates as potential antitumor or antibiotic agents, as they can inhibit DNA 
helicase activity [101].    In fact, Hoechst compounds were tested in human clinical trials 
for use in pancreatic cancer [102, 103].  Ultimately, the compounds were not approved 
due to lack of efficacy, but the compounds were tolerated at the up to 26 mg/m
2
 daily 
doses. Hoechst dyes are also cell permeable, a characteristic which has been leveraged 









 Due to neutral degradation products, polyketals are strong candidates for use in 
treating inflammatory diseases.  The polyketals are a unique class of degradable polymers 
in that they do not produce degradation products that can affect pH.  Most synthetic 
polymers used in drug delivery applications, such as polyesters and polyanhydrides, are 
based on linkages that produce acidic degradation products.  In cases where inflammation 
plays a central role, these changes in pH may have detrimental effects on the healing 
process or even affect therapeutic molecules [108].  This chapter highlights the use of 
PCADK microspheres as a drug delivery vehicle for a small molecule inhibitor of the p38 
MAPK pathway. 
 The development of suitable drug-delivery vehicles that can improve cardiac 
dysfunction following MI remains a major challenge in the field of biomaterials. 
Following acute MI, an excessive inflammatory response is initiated in the myocardium, 
causing chronic elevation of inflammatory cytokines and reactive oxygen species, 
resulting in cardiac dysfunction [10, 109-111]. A large number of clinically approved 
small molecule inhibitors have been identified that can suppress inflammation and have 
great potential for improving cardiac dysfunction. However, delivery remains a 
challenge, as many of these drugs require large doses and daily injections for efficacy and 
cause toxicity at these high doses [112-114].  Drug delivery vehicles that can sustain 
effective doses of therapeutics within the myocardium for weeks have the potential to 
slow or halt the progression of cardiac dysfunction [115].  Although biomaterials have 
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been developed for use in the heart, these materials have been designed to deliver protein 
therapeutics and cells, and are typically based on hydrophilic polymers that form 
hydrogels.  However, hydrophilic molecules are not well suited for the controlled release 
of hydrophobic drugs, such as small molecule inhibitors, because of their large pore sizes 
and low loading efficiency for compounds with high logP (logarithm of octanol/water 
partition coefficient; higher values represent more hydrophobic compounds) values [116, 
117].  Hydrophobic polyester-based microparticles have long been used to deliver 
hydrophobic drugs [118]; however, their use in cardiac drug delivery has not been fully 
investigated and the acidic degradation products pose some concern. 
 
Figure 3.1. Sustained cardiac delivery via PCADK microparticles.  Rats underwent permanent 
occlusion of the left anterior descending coronary artery (LAD) and received a direct intramyocardial 
injection of microparticles.  These microparticles were fabricated to have diameters in the 15-20 µm range 
so that they lodged in the myocardium rather than being cleared in the circulation.  Encapsulated compound 
was released over the course of weeks as they hydrolyzed or were degraded by macrophages. 
 
 Prior to this work, the biocompatibility of PCADK and its ability to deliver drugs 
to the heart was not fully characterized.  Biocompatibility was assessed by analyzing 
inflammatory pathways of cultured macrophages in response to PCADK microspheres.  
In addition, in vivo experiments were conducted in order to assess the cytokine and 
inflammatory response of muscle tissue in response to high doses of PCADK 
microspheres.  Upon establishing biocompatibility of the delivery vehicle, new 
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microparticles were fabricated containing SB239063, an inhibitor of the p38 MAPK 
pathway.  The p38 pathway has been shown to play a central role in cardiac dysfunction 
in both the activation of macrophages and the induction of apoptosis in cardiac myocytes 
[119-124].  The SB239063-loaded PCADK microparticles (PK-p38i) were directly 
injected into the hearts of rats that had undergone permanent left anterior descending 
coronary artery (LAD) ligation (Figure 3.1).  These microparticles released SB23063 as 
they were engaged and degraded by macrophages and other inflammatory cells. 
3.2 Results 
Microparticle Characterization 
 PCADK was synthesized as described in Appendix A with an average molecular 
weight of 6 kDa and polydispersity index of 1.9, as measured by gel permeation 
chromatography (GPC).  Microparticles were fabricated using a single-emulsion/solvent 
evaporation protocol as described in the appendix.  Since microparticle size could play a 
large role in the retention of microparticles in the heart tissue, control over size was 
determined by fabricating four batches of microparticles with different homogenization 
speeds (8500, 11500, 20000, and 30000 RPM).  In all cases, the polymer concentration 
was held constant at 100 mg/ml in dichloromethane (DCM).  Particles were then washed 
and dried, and examined using scanning electron microscopy (SEM) in order to 
determine microparticle diameter.  The size versus homogenization speed curve showed 
that we could generate between 0.8-18 µm diameter microparticles (Figure 3.2).  
Subsequent microparticles were fabricated using the slowest homogenization speed (8500 





Figure 3.2. Size versus homogenization speed relationship for PCADK microparticles.  Microparticle 
diameters were strongly dependent on the homogenization speed used to create the oil-in-water emulsion.  
Microparticle diameter was determined via SEM images.  (mean ± std. dev., three fields of view counted, 
total microparticles measured per group ≤200) 
 
 Microparticles containing SB239063 were formulated to have a maximal loading 
of 10 µg SB239063/mg microparticle.  Achieved loading efficiencies were on the order 
of 45%.  As a control, PLGA microparticles were also fabricated containing SB239063 
and had similar loading efficiencies and diameters (Figure 3.3). 
 In vitro release kinetics of SB239063 from PCADK microparticles were 
determined at pH 4.5 and 7.4 (Figure 3.4).  These pH values represent phagolysosomal 
and blood ranges, which should be indicative of release kinetics in vivo.  Microparticles 
were tested in either 100 mM acetic acid adjusted to pH 4.5, or phosphate buffered saline 
(PBS) adjusted to pH 7.4.  Microparticles were suspended in buffer and constantly 
agitated at 37ºC over the course of three weeks.  Tests with PCADK microparticles 
containing no inhibitor were also conducted in order to have a time-matched blank.  
Concentrations were determined spectrophotometrically at a wavelength of 320 nm.  
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released after three days.  By comparison, pH 7.4 samples only released 17% of 




Figure 3.3. PLGA and PCADK microparticles are size- and loading-matched.  SB239063 was 
encapsulated in PLGA and PCADK microparticles.  Identical protocols were used to fabricated the 
microparticles and produced similar sized and loaded microspheres.  (a-b) The mean diameters were 19.3 
and 17.9 µm for PLGA (a) and PCADK (b) microparticles, respectively.  (c) PLGA microparticles 
contained 3.4 µg/mg SB239063, which was slightly lower than the 4.5 µg/mg attained with PCADK 
microparticles. (mean±SEM, n≤3) (d) Representative scanning electron micrograph of PCADK 




















































Figure 3.4. In Vitro release kinetics of SB239063.  The release of SB239063 from PCADK microparticles 
was tracked over a period of three weeks at physiological (7.4) and lysosomal (4.5) pHs.  Both conditions 
showed similar release kinetics, with a greater burst release occurring at pH 4.5.  (mean±SEM, n=3, note: 
standard error for later time points are obscured by markers) 
In Vitro microparticle characterization 
 The effect of polymer microspheres on macrophage activation state was 
investigated using cultured RAW 264.7 cells.  Size-matched PCADK and PLGA 
microparticles – without encapsulated inhibitor – were incubated with RAW 264.7 cells 
for two, four, or six hours and cell lysate collected after treatment.  Western blots were 
run and probed for total- and phospho-p38 MAPK as a marker of activation state.  
Densitometry was used to quantify the macrophage response to the two different polymer 
chemistries (Figure 3.5).  PCADK microparticles did not show a significant increase in 
p38 MAPK phosphorylation whereas PLGA treated macrophages showed a statistically 
significant increase in phosphorylation at four and six hours.  At these time points, there 








































Figure 3.5. Effect of polymer chemistry on macrophage p38 MAPK activation in vitro.  Empty 
microparticles were incubated with RAW 264.7 macrophages and cell lysate analyzed for p38 MAPK 
activation by Western blot.  PCADK-treated macrophages showed no increase in p38 MAPK activation, 
whereas PLGA microparticles increased p38 MAPK phosphorylation over three-fold after four and six 
hours of incubation.  Representative Western blots show relative p-p38 MAPK levels. (mean±SEM, n=3,   
*p < 0.05 compared to control, Student’s t-test) 
 
 The bioactivity of encapsulated SB239063 was tested for loaded PCADK 
microparticles using a similar method.  RAW 264.7 macrophages were quiesced and pre-
treated with SB239063-loaded polyketal microparticles (PK-p38i) (2 µM SB239063, 0.15 
mg microparticles/ml) before being challenged with 10 ng/ml of tumor necrosis factor 
alpha (TNF-α), an activator of p38 MAPK, for 20 minutes (Figure 3.6a).  Empty 
microparticle controls (PK) had no effect on p38 MAPK activation and showed 1.75-2 
fold increase in phospho-p38 MAPK.  Macrophages treated with PK-p38i showed a time-
dependent response; macrophages treated for two hours did not show any reduction in 
phospho-p38 MAPK, whereas four hours of treatment reduced phospho-p38 MAPK to 
unchallenged levels.  Six hours of PK-38i treatment reduced p38 MAPK activation to 





















efficacy compared to free inhibitor (Figure 3.6b).  In this study, PK-p38i was incubated 
with cells for six hours before TNF-α stimulation and analyzed for p38 MAPK activation 
via Western blot.  PK-p38i and free SB239063 showed similar inhibition curves and half 
maximal inhibition concentrations (IC50) values in the 10
-7
 M range. 
      
Figure 3.6. In vitro bioactivity of encapsulated SB239063.  RAW264.7 macrophages were pretreated 
with microparticles before stimulation with TNF-α, which activates p38 MAPK.  Levels of phospho- and 
total-p38 MAPK were analyzed by Western blot and quantified using densitometry.  (a) Empty particles 
had no effect on levels of p38 MAPK activation.  Cells treated with 0.15 mg/ml of PK-P38i microparticle 
(2 µM SB239063) showed a time dependent response, suggesting that macrophages needed to engage and 
release sufficient inhibitor.  Representative Western blots show relative levels of phospho-p38 MAPK.  
(mean±SEM, n=3, *p < 0.05 compared to unchallenged cells, Student’s t-test) (b) Six hour pretreatment 
with various concentrations of microparticles showed similar efficacies when compared to free SB239063.  
IC50 values for both treatments fell in the 10
-7
 M range. (mean±SEM, n=3) 
 
 A downstream effect of p38 MAPK activation was additionally assayed using 
RAW264.7 cells in vitro.  Superoxide radicals are typically generated by activated 
inflammatory cells.  Cells were pretreated with microparticles, challenged with TNF-α, 
and then incubated with dihydroethidium (DHE), a probe for superoxide.  Results were 
quantified using high pressure liquid chromatography (HPLC) (Figure 3.7).  























































significantly higher levels of superoxide after TNF-α stimulation. PK-p38i treated cells 
did not show a statistically significant elevation of superoxide.  Inset shows 
representative traces, taken from heart tissue, of DHE-HPLC.  The peak at 14 minutes 
corresponds to 2-hydroxyethidium, the oxidation product of superoxide and DHE. 
 
 
Figure 3.7. DHE-HPLC quantification of superoxide production by RAW264.7 macrophages.  Cells 
were treated with microparticles and stimulated with TNF-α.  Downstream activation of p38 MAPK by 
TNF-α typically increases superoxide production.  Cells that received no treatment (SFM) or PK had 
significantly higher superoxide levels.  PK-p38i treatment reduced the amount of superoxide produced by 
macrophages in response to TNF-α.  Inset: representative HPLC traces observed with DHE-HPLC.  The 
peak corresponding to 2-hydroxyethidium/superoxide elutes at 14 minutes. (mean±SEM, n=3, *p < 0.05 
compared to unchallenged cells, Student’s t-test) 
In Vivo Biocompatibility of PCADK Microparticles 
 Rats were injected with a large dose (five milligrams) of either PLGA or PCADK 
microparticles in the thigh muscle.  The rats were sacrificed 72 hours post injection and 



















































CD45 (green), a cell surface marker for leukocytes, and for DNA with 4’,6-diamidino-2-
phenylindole dihydrochloride (DAPI, blue) (Figure 3.8).  Of note, the microparticles 
were also stained by DAPI; serial sections stained with H&E verified that the sections 
were at the injection site.  PCADK microparticles recruited few CD45 positive cells (a) 
whereas tissue injected with PLGA microparticles had a large influx of CD45 positive 
cells. 
 
Figure 3.8. Histological analysis of inflammatory cell recruitment of PCADK and PLGA 
microparticles.  Rats were injected with five milligrams of microparticles in the thigh muscle.  Three days 
post-injection, histological sections were stained with DAPI (blue) and anti-CD45 antibody (green).  CD45 
is a common marker for inflammatory cells.  DAPI is typically used to stain DNA, however PLGA and 
PCADK microparticles also took up the dye.  PCADK microparticles (a) recruited fewer CD45 positive 
cells compared to PLGA microparticles (b).  (scale: 100 µm) 
 
 In a separate study in mice, a Bioplex assay was used to determine the 
concentration of a panel of inflammatory cytokines at the injection site.  Bioplex assays 
are multiplexed enzyme linked immunosorbent assays (ELISA) on a bead tests that allow 
testing of multiple analytes using small sample volumes.  Mice were injected with either 
one milligram of PCADK microparticles or phosphate buffered saline (PBS) and 
cytokine levels tracked via Bioplex over three weeks.  Interleukin-1β (IL-1β) showed the 
only statistically significant increase of the cytokines tested at one day post injection; 






Figure 3.9. Cytokine response to intramuscular injection of microparticles.  PCADK microparticles (1 
mg) or PBS were injected into the thigh muscle of C57/B6 mice in order to assess cytokine response.  
Tissue concentrations of a panel of pro-inflammatory cytokines – (a) interleukin-1β, (b) interleukin-6, and 
(c) interferon-γ – was measured using a Bioplex assay. (inset: zoom of three and 21 day data, n.d. - not 















































































































two lower than PCADK treated animals.  IL-1β was elevated for both PBS and PCADK 
one day post injection and quickly returned to low levels at three, 8, and 21 days post 
injection.  The inset is a zoomed view for the later time points.  Similar results were seen 
with interleukin-6 (IL-6) and interferon-γ (IFN-γ); PCADK microparticles did not elevate 
pro-inflammatory cytokine levels in muscle tissue compared to saline injections at acute 
and chronic time points.  TNF-α and interleukin-12 were also assayed, but were not 
above the detection limit of this assay (<1 pg/ml, data not shown). 
In Vivo p38 MAPK Inhibition 
 The in vivo bioactivity of SB239063 was tested in a rat model of MI.  
Microparticles were directly injected into the myocardium immediately following LAD 
ligation.  At three and seven days post-MI, tissue was harvested and homogenized with 
protease and phosphatase inhibitors.  Western blots probing for phospho- and total-p38 
MAPK were run and quantified via densitometry.  Relative p38 MAPK activation was 
expressed as a ratio of phospho:total p38 MAPK (Figure 3.10a).  MI operated animals 
showed a greater than two-fold increase in p38 MAPK activation compared to sham 
operated animals.  Animals treated with free inhibitor (p38i) or PK showed similar levels 
of phospho-p38 MAPK at three and seven day time points.  PK-p38i treatment was able 
to significantly reduce the level of p38 MAPK phosphorylation compared to other groups 
that received MI at both time points.  However, PK-p38i was not sufficient to reduce p38 
MAPK phosphorylation to sham levels; PK-p38i treatment was 1.4-fold and 2-fold higher 
than sham at days three and seven, respectively. 
 Downstream markers of p38 MAPK activation were also measured in infarct 
tissue.  Superoxide production was measured using quantitative DHE-HPLC (Figure 
3.10b).  MI, MI + p38i, and MI + PK groups had between a two- to three-fold increase in 





     
Figure 3.10. In vivo inhibition of p38 MAPK and its downstream effects.  (a) PK-p38i treatment 
inhibited phosphorylation of p38 MAPK at three and seven days in the infarct zone, whereas free inhibitor 
(p38i) or PK had no effect on phosphorylation at either time point. (mean±SEM, n≥4, * p < 0.05 versus 
other treatment groups, ANOVA followed by Tukey–Kramer post-test) (b) Infarct zone tissue at three days 
was analyzed for superoxide using DHE-HPLC. MI alone, p38i, and PK had significantly greater 
superoxide levels compared with sham, whereas PK-p38i decreased the amount of superoxide produced. 
(mean±SEM, n≥4, * p < 0.05 versus other treatment groups, ANOVA followed by Tukey–Kramer post-
test) (c) The inflammatory cytokine TNF-α was measured in the infarcted zone by ELISA three days 
postsurgery. MI alone, free inhibitor, and empty particles had significantly greater amounts of TNF-α, 
whereas PK-p38i treatment reduced TNF-α levels nearly twofold. (mean±SEM, n≥4, * p < 0.05 versus 
other treatment groups, ANOVA followed by Tukey–Kramer post-test) 
 
amount of superoxide compared to other groups that received MI surgery.  Furthermore, 
2-hydrodroxyethidium levels were on the order of sham operated animals (9.9 nmol/mg 
















































































 Concentrations of the pro-inflammatory cytokine TNF-α in the heart were 
analyzed via ELISA.  Results mirrored p38 MAPK activation data with significant 
elevation of TNF-α levels in animals that received MI, regardless of treatment (Figure 
3.10c).  PK-p38i treatment significantly reduced TNF-α compared to other MI groups 
(103.6 pg TNF-α/mg protein compared to >150 pg TNF-α/mg protein for other MI 
groups), but was still two-fold higher than sham operated animals (53.6 pg TNF-α/mg 
protein). 
Cardiac Function 
 Cardiac function of the rats was monitored at seven and 21 days post-MI using 
magnetic resonance imaging (MRI).  MRI images were used to calculate fractional 
shortening of the left ventricle and expressed as a percentage (Figure 3.11).  Sham 
operated animals maintained healthy heart function with fractional shortening in the 50% 
range.  Animals that received LAD ligation had reduced fractional shortening values in 
the 35-40% range, regardless of treatment group; neither free inhibitor nor any 
microparticle treatment was able to prevent loss of function at one week.  At three weeks, 
untreated MI, p38i, PK, PLGA, and PLGA-p38i treatments all showed further decreases 
in fractional shortening levels.  PK-p38i treatment showed recovery of function between 
days seven and 21; fractional shortening for PK-p38i treated animals increased from 35% 
to 45%, representing a ten percent improvement (absolute value).  PK-p38i treatment was 
the only group to have a statistically significant (p < 0.01) improvement improvement in 
fractional shortening between these time points. 
 Given the late improvement in cardiac function, we examined the levels of 
fibrosis as a potential explanation.  Fibrosis is part of the chronic inflammatory response 
and typically manifests on the order of weeks post infarction in rats.  Hearts were 
harvested and section for histological analysis.  Picrosirius red stain was used to stain 
collagen (red, compared to surrounding orange tissue) in the sections.  Sections were 
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imaged and analyzed digitally in order to quantify the percentage of fibrotic area (Figure 
3.13a).  Sham operated animals, as expected, had very low levels of fibrosis (2%), MI 
operated animals  that received p38i, PK, or no treatment exceeded 30% fibrosis, whereas 
PK-p38i treatment had only 15.6% fibrosis.  This drop for PK-p38i treatment represents a 
significant decrease compared to other MI operated groups, but not quite down to sham 
levels of fibrosis. 
 
Figure 3.11. PK-p38i treatment resulted in increased cardiac function between days seven and 21.  
Dimensions of the left ventricle were measured at systole and diastole using MRI at day seven and day 21 
post-MI. PK-p38i showed a statistically significant difference between days seven and 21, whereas all other 
treatments did not reach significance (mean±SEM, n≥4, * p < 0.05, repeated-measures ANOVA). In 
addition, PK-p38i fractional shortening was significantly higher on day 21 compared with MI alone and all 
other MI-treatment groups (ANOVA followed by Tukey–Kramer post-test). Of note, PK-p38i treatment 
showed a significant 10% improvement (absolute value) in cardiac function, whereas PLGA-p38i and 
soluble SB239063 (p38i) treatments showed a trend towards decreased cardiac output. 
  
In order to compare cardiac function across treatment groups, the change in 
fractional shortening between days seven and 21 was calculated (Figure 3.12).  Positive 

























































progression towards cardiac dysfunction.  Rats treated with PK-p38i showed the only 
statistically significant improvement (p < 0.01), with a positive gain of 9.7±1.8 fractional 
shortening percentage points.  Rats that were treated with PLGA-p38i microparticles 
showed a decrease in fractional shortening (-3.7±1.2%), while free inhibitor (p38i) had a 
non-statistically significant increase of 3.7±1.1%. 
 
 
Figure 3.12. Change in fractional shortening between days seven and 21.  Fractional shortening was 
measured and expressed as an absolute percentage difference between days seven and 21.  Positive values 
represent improvement in cardiac function, whereas negative values represent progression towards heart 
failure.  PK-p38i treatment showed a significant 9.7±1.8% improvement (absolute fractional shortening 
value), while PLGA-p38i treatment showed a decrease (-3.7±1.2%) in fractional shortening.  (mean±SEM, 


















































Figure 3.13. PK-p38i therapy reduced fibrotic area in the heart. The left-ventricular free wall was 
analyzed histologically in at least three serial sections for fibrosis using a collagen-specific Picrosirius Red 
stain. (a) MI-alone, free-inhibitor and empty-particle treatments had significant increases in fibrosis 
compared to sham operation. PK-p38i treatment reduced fibrotic area by more than half, though not 
completely to sham levels. (mean±SEM, n ≥4, * p < 0.05 versus other treatment groups, ANOVA followed 
by Tukey–Kramer post-test) (b-e), Representative Picrosirius Red images of MI (b), MI+free inhibitor (c), 




























 Microspheres formulated from the polymer PCADK can encapsulate the p38 
MAPK inhibitor SB239063, can improve the treatment of cardiac dysfunction.  PCADK 
is a recently developed, acid-sensitive polymer that has great potential for treating 
inflammatory diseases, such as cardiac dysfunction, because it degrades into the neutral, 
excretable, FDA-approved compounds 1,4-cyclohexane dimethanol (approved by the 
FDA as an indirect food additive) and acetone (an endogenous compound with potential 
antioxidant properties) and thus should not exacerbate any existing inflammation [125, 
126] (Figures 3.8 and 3.9).  Furthermore, SB239063 is hydrophobic (logP of 3.5), and 
therefore microspheres of tailor made sizes can be created from a single emulsion process 
(Figure 3.2).  The p38 MAPK pathway is central in activating macrophages and inducing 
apoptosis in cardiomyocytes, and thus represents a candidate for therapy in the heart 
[119-124].  We therefore hypothesized that a direct injection of large PCADK 
microparticles loaded with SB239063 (PK-p38i), 10-20 microns in size, would be 
retained in the myocardium to slowly release the small molecule inhibitor.  This 
therapeutic strategy leverages PCADK’s pH-sensitivity as the microparticles will be 
stable in the infarct zone, but are capable of being hydrolyzed by macrophages, which are 
already prevalent in the infarct zone.  As macrophages engage the microspheres, small 
PCADK particles would be exposed to acidic phagosomes, or macrophages may degrade 
particles, thus increasing the release of an encapsulated drug (Figure 3.1). 
 The degradation products of microparticles frequently cause the activation of 
inflammatory proteins in macrophages and is a critical issue limiting the use of 
microparticles for the treatment of inflammatory diseases.  We therefore investigated if 
degradation of PCADK microparticles by macrophages caused the activation of p38 
MAPK itself and compared this to the response to PLGA microparticles as a control.  
Macrophages were incubated with PCADK or PLGA microparticles (15-20 µm diameter) 
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for 2, 4, or 6 hours, harvested and analyzed by Western blotting for p38 phosphorylation.  
Figure 3.5 demonstrates that PLGA induced time-dependent increase in p38 MAPK 
phosphorylation, suggesting elicitation of inflammatory pathways, whereas PCADK did 
not.  These data agree with published reports showing PLGA treatment increases 
inflammatory cytokine production in cultured cells [7, 8] and also demonstrates that 
PCADK has potential as a drug delivery vehicle designed to inhibit p38 MAPK 
activation.  
  The ability of PCADK microparticles to encapsulate the p38 MAPK inhibitor 
SB239063, and the bioactivity of these microparticles was investigated using RAW 264.7 
macrophages in vitro.  A single emulsion procedure that was designed to maximally 
produce microparticles with 10 µg of inhibitor per mg of PCADK; the obtained 
encapsulation efficiency of SB239063 was 44±7%, and PK-p38i microparticles had 3-5 
µg of inhibitor per mg of PCADK (Figure 3.3).  To test bioactivity, macrophages were 
treated with either PK-p38i or empty PCADK particles (PK) for 2, 4, or 6 hours, washed 
and stimulated for 20 minutes with TNF-α.  As the representative blot and grouped data 
demonstrate, PK-p38i but not PK, prevented p38 phosphorylation by TNF- α stimulation 
in a time-dependent manner (Figure 3.6a).  Additionally, both the free inhibitor and PK-
p38i demonstrated similar dose-response profiles, suggesting little loss of SB239063 
activity in PK-p38i microparticles (Figure 3.6b).  The release half life of SB239063 from 
PCADK microparticles is 10 days at pH 7.4 (Figure 3.4), and thus on the basis of these 
release kinetics, only 1.9% of encapsulated inhibitor (or 120 pmol) would be released 
into the media over the duration of the six hour experiment.  These results also suggest 
that macrophages are playing an active role in inducing the release of SB239063 from 
PK-p38i microparticles, either through phagocytosis of the microparticles, leading to 
intracellular release of the inhibitor, or through fusion of their phagosomes with the 
microparticles, leading to extracellular release of the inhibitor.  In keeping with this, we 
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found no inhibition of TNF-α stimulated p38 MAPK phosphorylation in cultured 
neonatal cardiac myocytes, suggesting the potential involvement of a cell-mediated 
mechanism (data not shown).   
 We also investigated if PK-p38i microparticle mediated inhibition of p38 MAPK 
activation also led to a reduction in downstream inflammatory effectors, in particular 
superoxide.  Cultured macrophages were incubated with PK-p38i microparticles or empty 
PK microparticles, stimulated with TNF-α and then assayed for extracellular superoxide 
production.  Superoxide production was investigated by measuring accumulation of a 
superoxide-specific product of DHE, 2-hydroxyethidium by DHE-HPLC [127, 128].  As 
the data in Figure 3.7 demonstrate, PK-p38i pretreatment reduced TNF-α-induced 
superoxide production while PK had no effect.  These data demonstrate that PK-p38i is 
active in reducing p38 MAPK phosphorylation, as well as clinically relevant p38 MAPK-
dependent second messenger generation. 
  A key issue involving microparticle drug delivery in vivo is the immune response 
associated with foreign bodies; in general, immune cells are recruited to the area of the 
microparticles and remain there until the microparticles are metabolized and 
phagocytosed, thus compromising their function.  If the acute inflammatory response 
cannot remove the foreign body, it is often encapsulated with fibrotic tissue.  The foreign 
body response is particularly severe with particles that have acidic degradation products.  
In contrast PCADK may minimize the foreign body response because it generates neutral 
degradation products.  In order to compare the tissue biocompatibility of PCADK and 
PLGA microparticles, rats were subjected to an intramuscular injection of size matched 
PLGA or PCADK microparticles (100 µl of 50 mg/ml), sacrificed at three days, and 
histological sections of the injection site were made and stained for CD45, an 
inflammatory cell marker.  Figure 3.8 demonstrates that PLGA microspheres generated a 
large influx of CD45-positive cells (Figure 3.8b), in agreement with prior studies 
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demonstrating in vivo inflammation associated with PLGA delivery [129].  In contrast, 
PCADK microparticles caused very little recruitment of CD45-positive cells (Figure 
3.8a).  We further investigated the inflammatory response to PCADK microparticles with 
quantitative cytokine analysis.  Mice were subjected to an intramuscular injection of 
either saline (vehicle) or PCADK microparticles (100 µl of 10 mg/ml) and leg muscles 
were harvested at acute and chronic time points (1, 3, 8, and 21 days).  We found that 
while PCADK briefly increased levels of interleukin-1β (IL-1β) levels on day one, there 
was no significant increase subsequently (Figure 3.9a).  Additionally, there was no 
significant increase in IL-6 (Figure 3.9b) or interferon-gamma (Figure 3.9c) at any time 
point, while levels of TNF-α and IL-12 were below detection limits (data not shown).  
These data suggest that PCADK microparticles do not induce an inflammatory response, 
at concentrations far exceeding those needed for drug delivery applications, and can 
therefore be used as a delivery vehicle for the treatment of inflammatory diseases. 
 PK-p38i microparticles were tested in a rat model of MI, as described in the 
methods.  In preliminary experiments, PCADK microparticles with diameters in the 20 
µm range remained in the myocardium for several days, most likely because their size 
precluded them from being carried away in the microcirculation.  Following coronary 
artery ligation, treatments were injected intramyocardially in 100 µl volumes in a 
randomized and double-blinded fashion.  Treatment conditions were vehicle, free 
inhibitor (2 µM), PK (0.5 mg particle/mL), or PK-p38i (0.5 mg/mL corresponding to 2 
µM SB239063) injected directly into the left ventricular free wall.  At three and seven 
days following ligation, treatment with PK-p38i significantly inhibited p38 MAPK 
phosphorylation within the infarct zone, while free inhibitor and PK had no effect 
(Figure 3.10a).  These data suggest that PK-p38i is able to provide sustained p38 MAPK 
inhibition in the myocardium for at least seven days.  Free SB239063 injections were not 
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effective in inhibiting p38 MAPK phosphorylation since the free inhibitor was likely 
cleared rapidly from the tissue.   
 Given that in vitro data suggest that phagocytosis is important for the release and 
bioactivity of SB239063 from the microparticles, one of the key questions in vivo is how 
global p38 MAPK inhibition is achieved, especially in non-phagocytic cell types.  Since 
the microparticles injected had a distribution of sizes, there are two likely hypotheses that 
would explain global p38 MAPK inhibition in the infarct.  Smaller particles (<5 µm 
diameter) were likely phagocytosed by inflammatory cells.  The decreased pH of 
phagolysosomes would likely accelerate PCADK hydrolysis and subsequent SB239063 
release.  The released inhibitor could then directly inhibit p38 MAPK in the inflammatory 
cell or diffuse across the cell membrane and act upon surrounding, non-phagocytic cell 
types (i.e. cardiac myocytes).  A second hypothesis involves inflammatory cell 
interaction with larger microparticles that cannot be phagocytosed.  Cannon and Swanson 
[130] demonstrated that particle phagocytosis was dependent on cell membrane surface 
area.  Beyond a threshhold of 15-20 µm diameters, cells cannot engulf particles based on 
surface area considerations.  Under these cases, inflammatory cells may fuse their 
phagolysosome with the foreign body, causing surface degradation of the polymer 
microparticle.  This route could release compound directly into the myocardium, thus 
affecting both phagocytic and non-phagocytic cells. 
 Because chronic p38 MAPK inhibition has been shown to reduce levels of 
superoxide during heart failure [131], infarct zone tissue from three day samples was also 
analyzed for the production of superoxide using DHE-HPLC.  As the grouped data in 
Figure 3.10b demonstrate, PK-p38i treatment significantly reduced superoxide levels 
while free inhibitor and PK had no effect.  Another downstream product of p38 MAPK 
activation, TNF-α production, was also measured and similarly only PK-p38i treatment 
was able to significantly reduce this inflammatory cytokine (Figure 3.10c). 
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 In addition to in vivo biochemical findings supporting the in vitro data, the 
functional outcome of microparticle treatments was measured in separate randomized and 
double-blinded studies.  In these functional experiments, several treatment groups were 
tested (Sham, MI, PK, PK-p38i) with  a separate randomized and blinded study 
conducted to test PLGA and PLGA microparticles loaded with the p38 MAPK inhibitor 
SB239063 (PLGA-p38i).  We choose to compare the efficacy of PLGA-p38i 
microparticles with PK-p38i microparticles to determine if polymer chemistry had an 
influence on therapeutic efficacy in vivo.  The PLGA-p38i and PK-p38i microparticles 
were matched in both size and loading efficiency (Figure 3.3).  Cardiac function was 
assessed using MRI and echocardiography seven and 21 days post-infarction and 
dimensions of the heart were measured in a double blinded manner. While the 
biochemical data would suggest an immediate effect on function, no significant 
improvement with any treatment at seven days post-infarction was found (Figure 3.11; 
white bars).  At 21 days however, there was a significant improvement in fractional 
shortening in PK-p38i treated rats, while no effect was seen with free inhibitor, PK, 
PLGA, or PLGA-p38i particles (Figure 3.11; gray bars).  While there was no initial 
improvement or blunting of loss of cardiac function over the first week, sustained p38 
MAPK inhibition slowed the progression of the dysfunction, even demonstrating 
improvement over time.  We believe this can be explained by the fact that significant 
damage from MI by apoptosis and necrosis is done within the first 24-48 hours [15].  As 
the release half-life of the particles is seven days and macrophage infiltration takes hours-
to-days, it is likely that the inhibitor was not released fast enough to affect this early time 
point.  Thus future studies will examine the effect of generating faster hydrolyzing 
particles to combat this.   
 Given that the effect on function was not seen early, we hypothesized that 
prolonged p38 MAPK inhibition was having an effect on development of fibrosis [132, 
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133].  Histological sections were made from the rats at 21 days post-infarction and 
stained for collagen using Picrosirius Red.  Digital images of the sections were captured 
and quantified manually in a blinded manner (Figure 3.13a).  Untreated MI, free 
inhibitor, and PK particle treatment had significantly more fibrosis than sham operated 
animals (Figures 3.13b-e).  Treatment with PK-p38i resulted in significantly less fibrosis 
in comparison to other treatment conditions (Figure 3.13e).  These data, taken together 
with the functional data, suggest that a single injection of PK-p38i microparticles reduced 
fibrosis and progression of cardiac dysfunction following myocardial infarction. 
 There is a compelling need for development of new biomaterials that can improve 
the treatment of myocardial infarction.  In this chapter, the polyketal PCADK was 
demonstrated to have the biocompatibility and hydrolysis properties needed for treating 
inflammatory diseases.  PCADK microparticles do not induce an inflammatory response 
in vitro or in vivo, and can therefore reside in inflamed tissue and act as a controlled 
release reservoir for SB239063, having a release half-life of seven days for SB239063 at 
neutral pH values.  We also demonstrate that PCADK microparticles loaded with 
SB239063 results in prolonged reduction of inflammatory signaling and eventual 
increased functional outcome from a single injection.  In a direct comparison with PLGA, 
only loaded PCADK microparticles significantly improved function over time.  Based on 
these results, polyketals represent a promising class of materials for treatment of 




IMMOBILIZED METAL AFFINITY DRUG DELIVERY SYSTEMS 
 
4.1 Introduction 
 Microparticle drug delivery systems have been used for over twenty years to 
deliver a variety of drugs and therapeutics.  These systems work well for delivery of 
small molecule drugs.  However, effective microencapsulation of proteins has been 
limited by low encapsulation efficiencies and high risk of protein denaturation.  This 
chapter describes the adaptation of a widely used immobilized metal affinity protein 
purification strategy to non-covalently attach proteins to the surface of microparticles for 
drug delivery purposes.  
 IMAC was first described by Porath, et al. in 1975 [134], and has made 
production of purified recombinant proteins possible in large scale with high purities.  
While several affinity tag systems exist, one of the most common relies on interactions 
between chelated metal complexes and sequential histidine residues (six histidines are 
commonly used in a His-tag).    Inspired by IMAC chemistry, polyketal microparticles 
were surface functionalized with NTA in order to non-covalently tether proteins to 
polyketal microparticle surfaces.  Surface modification may allow for dual delivery of 
therapeutics that prevent cardiac dysfunction on different time scales (i.e. hours versus 
weeks). 
 Polyketal microparticles were surface modified with nitrilotriacetic acid-nickel 
(NTA-Ni) complexes, which have a high affinity for sequential histidine residues (on 
proteins (Figure 4.1).  This high affinity interaction can efficiently capture proteins from 
dilute solutions with little risk of protein denaturation.  Proteins that bind to the NTA-Ni 
complex retain bioactivity and can diffuse away from the microparticles to activate cells 
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from a distance.  In addition, this surface modification can also be used for microparticle 
targeting by tethering cell-specific ligands to the surface of the particles.  In this study, 
protein release kinetics of model His-tagged proteins from the NTA-Ni complex were 
studied and it was demonstrated that bioactive molecules could be released and act on 
cells at a distance.  Furthermore, targeting specific cell types was attempted by tethering 
cell surface marker ligands to microparticles.  Lastly, potential toxicity issues that could 
arise due to incorporation of heavy metal ions into the drug delivery vehicle were 
investigated. 
 
Figure 4.1. Scheme for  incorporating NTA-Ni complexes on the surface of microparticles.  1,2-
dioleoyl-sn-glycero-3-[(N-(5-amino-1-carboxypentyl)iminodiacetic acid)succinyl] (DOGS-NTA), shown in 
the shaded box, is an amphiphilic lipid that has the ability to chelate metals.  Microparticles can be surface 
functionalized by simply mixing the lipid in the organic phase of an emulsion.  During the drying process, 
the hydrophilic chelating group migrates to the aqueous interface of the microparticle and is anchored by 
the hydrophobic lipid tail in the polymer matrix.  One the microparticles are fully dry, nickel can be added 
to the NTA group and His-tagged proteins non-covalently tethered. 
4.2 Results 
Surface functionalized PCADK microparticles 
 Polyketal microparticles were functionalized by adding DOGS-NTA (shaded box 
in Figure 4.1) to the organic phase of a single-emulsion polyketal microparticle.  The 
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lipid tail serves as an anchor for the more hydrophilic NTA moiety, which migrates to the 
surface of the microparticle.  Microparticles were analyzed using scanning electron 
microscopy (SEM) (Figure 4.2a) and found to have diameters that ranged from 10-20 
μm.   
                        
    
Figure 4.2. Micrographs of NTA functionalized microparticles. (a) Scanning electron micrograph of 
PCADK microparticles functionalized with 10 wt% NTA. (scale: 20 µm).  (b) Microparticles incubated 
with PBS, which does not contain nickel, and then with His-GFP showed little green fluorescence under 
epifluorescent microscopy.  (c) Microparticles that were incubated in 50 mM NiCl2 solution prior to 






 Proof of protein tethering was assessed using His-tagged green fluorescent protein 
(His-GFP).  Polyketal particles containing NTA that were pretreated with PBS, followed 
by washing, and exposure to a 100 nM solution of His-GFP showed little fluorescence 
when examined under fluorescence microscopy (Figure 4.2b).  In contrast, particles that 
were pre-incubated in a 0.05M NiCl2 solution prior to incubation with His-GFP exhibited 
extensive green fluorescence around the microparticles (Figure 4.2c). 
Quantitative measurement of His-GFP loading 
 The binding capacity of two formulations of NTA-functionalized microparticles 
was determined quantitatively using a modified ELISA to determine the amount of GFP 
on the surface of the microparticles.  Both 1 wt% and 10 wt% NTA-Ni microparticles 
showed similar His-GFP binding properties (Figure 4.3).  Microparticles that were 
loaded at concentrations of less than 1 µg His-GFP/ml showed a linear loading profile 
with a slope corresponding to approximately 40% loading efficiency relative to the total 
amount GFP in solution.  The 1% NTA formulation saturated at a loading concentration 
of 800 ng His-GFP /ml, while the 10% NTA formulation had a higher saturation point at 
1200 ng His-GFP /ml.  These loading capacities correspond to a mass dose of 330 ng 




Figure 4.3. Loading capacities for 1% and 10% NTA formulations.  Microparticles containing either 
1% or 10% NTA were loaded with nickel and incubated in His-GFP solutions ranging from 0-1400 ng/ml.  
Particles were extensively washed and the amount of bound GFP was determined using a modified ELISA 
protocol.  Both formulations showed similar linear loading capacities, corresponding to 40% loading 
efficiency.  Ten percent formulations saturated at 1200 ng GFP/ml whereas 1% formulations peaked at 800 
ng GFP/ml, which corresponded to mass doses of 440 ng GFP/mg particle and 330 ng/mg particle, 
respectively. (mean±SEM, n=3) 
Particle release studies 
 Release studies were conducted from the surface and core of the particles using 
two model compounds, His-GFP and rhodamine-B (Figure 4.4).  The core of the 
microparticles was loaded with 2 wt% rhodamine-B while the surface was loaded with 
His-GFP.  The release study was conducted under physiological conditions (pH 7.4, 
37°C).  His-GFP was released with a release half life of 2 h with complete release 
occurring at 48 h.  Rhodamine-B showed an initial burst of approximately 39% released 
in the first 12 h, with slow release occurring over the next week.  A more hydrophobic 
compound, SB239063, was previously shown to have significantly slower release 























Figure 4.4. Release kinetics for model compounds.  Release studies were conducted for a model protein, 
His-GFP, and two encapsulated compounds, rhodamine-B and SB23063.  His-GFP was released relatively 
rapidly compared to the encapsulated inhibitors. (mean±SEM, n=3) 
 
In vitro metabolic assays 
 Changes in metabolic activity for two cell lines, neonatal cardiac myocytes 
(NCM) and RAW264.7 murine macrophages were measured following exposure to 
microparticles by MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide] 
assay.  This assay measures mitochondrial activity of viable cells.  NTA-functionalized 
particles that were pre-incubated with PBS or NiCl2 were tested at doses ranging from 
0.25 mg/ml to 2 mg/ml and compared to untreated cells (control) and cells treated with 1 
mg/ml of unmodified PCADK microparticles.  Neonatal cardiac myocytes treated with 
NTA microparticles had metabolic activities ranging from 78-92% of control-treated 
while neonatal cardiac myocytes treated with NTA-Ni microparticles showed no 




























Figure 4.5. Metabolic activity of cells treated with microparticles.  MTT assays were used to determine 
the viability to two different cell types, RAW 264.7 macrophages and neonatal cardiac myocytes, after 
exposure to microparticles.  NTA or NTA-Ni microparticles did not show any appreciable toxicity 
compared to PCADK microparticles (1 mg/ml) for either cell type after six hours of treatment.  In all cases, 
cell viability was ≤75% compared to untreated cells.  Total mass doses given to cells in these experiments 
were at least two times greater than total mass doses administered to animals in previous studies.  
(mean±SEM, n=3) 
 
 RAW cells treated with 2 mg/ml of either type of modified particle showed 
similar metabolic activity compared to RAW cells treated with non-modified PCADK 




















































microparticles (82-83% metabolic activity).  Lower doses of microparticles showed 
higher metabolic activities, while concentrations of 0.25 mg/ml of NTA and NTA-Ni 
particles showed similar activity to control-treated cells.  No significant difference in 
metabolic activity between nickel-loaded and nickel-free particles was observed (Figure 
4.5b). 
Delivery of VEGF to HUVEC 
 In order to determine whether proteins loaded on the surface retain biological 
activity, human umbilical vein endothelial cells (HUVECs) were treated with 
microparticles that were surface loaded with NTA-Ni and His-tagged vascular endothelial 
growth factor (VEGF).  All microparticles were previously loaded in a 1 µg/ml solution 
of His-VEGF before washing and suspension in serum free media.  Cells were incubated 
with doses ranging from 0.01-1 mg microparticles/ml for a period of 20 minutes.  The 
bioactivity of the delivered VEGF was measured by Western blot analysis of cell lysates 
probed with phospho-VEGF receptor-2 (VEGFR2) and total VEGFR2 antibodies.  
Densitometric measurements of the blots were made and the ratio of phosphorylated:total 
VEGFR2 was calculated.  Cells that were treated with PK-VEGF showed a dose 
dependent increase in VEGFR2 phosphorylation, with an 8-fold increase at a 2 mg/ml 
dose (Figure 4.6a) with no effect of lower doses (0.01 mg particles/ml and 0.05 mg 
particles/ml).  HUVECs treated with NTA microparticles incubated with VEGF, but 
should not contain tethered VEGF due to the lack of nickel, did not show any change in 
VEGFR2 phosphorylation compared to control cells (Figure 4.6b).   
 In order to demonstrate that the VEGF tethered to the microparticle could be 
released from the surface over time in its active form, cells were treated with PK-VEGF 
microparticles using a transwell assay with cells on the bottom of the well, and the 
particles on the top.  Particles were added to the transwell at a concentration of 1 mg 
microparticles/ml in an equal volume as the amount of media on the cells below the 
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transwell for a final effective concentration of 0.5 mg microparticles/ml.  The pore size 
chosen was 3 µm to ensure that particles with tethered VEGF could not activate the cells 
directly.  HUVECs did not show activation of VEGFR2 after 20 minutes of PK-VEGF 
treatment across a transwell membrane (data not shown).  However, receptor 
phosphorylation was prevalent after 1, 2, and 3 hours of treatment (Figure 4.6c).  
 
Figure 4.6. Activation of VEGFR2 by VEGF-loaded NTA-Ni Microparticles.  HUVEC were treated 
with microparticles and Western blot analysis was used to determine the extent of VEGFR2 
phosphorylation.  (a) Microparticles loaded with nickel and then incubated with His-VEGF showed a dose 
dependent response in VEGFR2 phosphorylation.  (b) Microparticles containing only NTA, with no nickel, 
and incubated with His-VEGF did not show activation of VEGFR2 at any of the doses tested. (c) 
Microparticles incubated in a 3 µm transwell assay tested the ability of VEGF to diffuse from the 
microparticle surface and activate cells at a distance.  No activation was seen at 20 minutes (data not 
shown), but sustained VEGFR2 phosphorylation was seen after 1, 2, and 3 hours of incubation. 
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Cell surface receptor targeting 
 Small microparticles (1~2 μm) were fabricated containing either 1 wt% coumarin-
6 or rhodamine-B and 10% NTA in order to assess the potential of targeting 
microparticles to specific cell types.  Coumarin-6 and rhodamine-B were used a 
fluorescent tracers for the microparticles.  Polyketal microparticles containing NTA-Ni 
were surface loaded with His-tagged VE-Cadherin, a protein specific to endothelial cells 
that forms homodimers with high affinity.  Two cell lines were tested for targeting, 
HUVECs (which express VE-Cadherin) and rat neonatal cardiac myocytes (negative 
control).  Cells were incubated with VE-Cadherin loaded microparticles for 3 hours, 
washed thoroughly, and imaged under fluorescence microscopy.  Our data show 
extensive binding of microparticles functionalized with VE-cadherin to endothelial cells 
(Figure 4.7a) with little binding of non-loaded NTA-Ni microparticles to HUVECs 
(Figure 4.7b).  Examination using confocal microscopy suggested that the particles were 
not internalized by the cells (Figure 4.8).  Cells that were positive for at least one 
fluorescent microparticle were counted and expressed as a total percentage of the cells in 
the field of view (Figure 4.9).  Three negative control conditions (HUVECs treated with 
NTA-Ni particles not loaded with VE-Cadherin and NCMs treated with both types of 
particles) showed that approximately 20% of cells had at least one particle attached.  
HUVECs treated with VE-Cadherin loaded microparticles had a greater than two-fold 
enhancement of microparticle targeting with nearly half of the cells being positive for at 




Figure 4.7. Fluorescence micrographs of HUVECs targeted via VE-Cadherin interactions.  
Microparticles were loaded with coumarin-6 and incubated with cells at a concentration of 0.1 mg/ml for 
3h and washed extensively to remove unbound particles.  Cells were then fixed and imaged under 
epifluorescence microscopy in order to count cells (stained green) that were positive for at least one 
microparticle (yellow) (a) Microparticles loaded with VE-Cadherin were present on nearly half of HUVEC.  
(b) NTA-Ni particles without VE-cadherin only labeled 20% of cells.  (scale: 100 µm) 
 
 
Figure 4.8. Scanning laser confocal micrograph HUVEC with VE-Cadherin loaded microparticle. 





Figure 4.9. Quantification of HUVEC targeting.  Negative controls (HUVEC + Ni-NTA, NCM + VE-
Cadherin, NCM + Ni-NTA) ranged from 19 to 26% of cells positive for one microparticle. By contrast, 
HUVECs incubated with VE-Cadherin loaded microparticles had 45.7% of cells labeled by microparticles, 
which represents a 2.4-fold increase compared to HUVECs treated with non-targeted microparticles 
(mean±SEM, n=3). 
4.3 Discussion 
 Biological-based therapeutics, such as proteins and nucleic acids, have the 
potential to treat a variety of diseases due to their great specificity and high potency.  
However, delivery of biological compounds presents many challenges for drug delivery 
vehicles due to their sensitive structural properties and hydrophilicity.  The data 
presented in this chapter suggest that metal affinity based systems are a simple, yet 
effective way to functionalize microparticle carriers in order to obtain microparticle 
targeting as well as delivery of a protein payload with little risk of denaturation. 
 Other studies examining the use of NTA-modified surfaces have covalently 
attached NTA to polystyrene microparticles through a condensation reaction [61] for use 
in flow cytometry.  These techniques require several steps to achieve conjugation and 

































readily modified due to the difficulty in incorporating reactive chemical handles onto the 
polymer backbone.  However, surface modification using DOGS-NTA is widely 
applicable regardless of polymer system.  Due to the amphiphilic nature of the DOGS-
NTA conjugate, we hypothesized that we could add the lipid to the organic phase of the 
emulsion and allow the hydrophilic NTA-head groups to migrate to the surface of the 
microparticle.  This one-step procedure does not depend on specific chemical groups and 
only depends on the emulsion and drying parameters.  Thus DOGS-NTA was 
incorporated without any major alterations in particles size from prior studies.   
 Our data suggest that protein loading has a weak dependence on NTA 
incorporation at the concentrations used in this study.  Ten percent NTA microparticles 
had a slightly greater capacity with 440 ng GFP/mg microparticle compared to 330 ng 
GFP/mg microparticle for the 1% NTA formulation (Figure 4.3), though maximal 
percent loading remained fairly constant.  These loading fractions represent 
physiologically relevant doses for in vivo applications; growth factors often have effects 
at nanomolar concentration, which corresponds to nanograms of protein delivered locally 
[115].  More importantly, protein loading was achieved in purely aqueous conditions 
using dilute (<2 μg /ml) solutions of protein; typical double emulsion procedures use 
protein concentrations in excess of 10 mg/ml [125].  Such high concentrations and 
protein waste may not be acceptable for expensive proteins that are hard to purify or for 
scaled-up commercial applications.  In addition, protein that does not bind to the surface 
of the microparticle with the NTA-Ni system is completely recoverable in this loading 
procedure by centrifuging the particles and recovering the supernatant.  This binding was 
completely reversible as incubation of particles with saturating concentrations (>100 
mM) of imidazole-induced immediate release (data not shown).  Given the wide 
popularity of His-tags for purification of recombinant proteins, a large, existing library of 
proteins can be readily used with the system.  Surface functionalization is amenable to 
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screening combinatorial therapies without the need to fabricate a new batch of 
microparticles for a given protein combination; instead, microparticles can be loaded in a 
complex, aqueous mixture of therapeutic proteins or targeting ligands.  Furthermore, the 
concept of delivering multiple therapeutics can be taken one step further by the 
encapsulation of small molecules.  As illustrated in Figure 4.4, different release kinetics 
of an encapsulated compound can be achieved due to the physicochemical properties of 
the drugs or the polymer [136]. Further tuning of the release rates may potentially be 
achieved by altering the number of NTA groups as well as the length of the His-tag [60].  
These techniques may offer ways to modulate the release kinetics of metal affinity 
systems.   
 One potential concern for metal-affinity delivery systems is potential toxicity 
from the metal ions.  While heavy metals have been shown to be detrimental, especially 
in environmental contamination situations, the amount of nickel used in this system is far 
below toxic concentrations.  Ten percent NTA-Ni polyketal formulations maximally 
contain 5.8 nanograms of nickel per milligram of microparticle.  In order to put this into 
perspective, the average American diet contains 300 micrograms nickel per day [137].  In 
addition, chelated metals have been shown to have reduced toxicity compared to their 
free ion counterparts [138].  Our MTT data suggest that NTA-functionalization, with or 
without nickel, does not add any additional toxicity compared to PCADK microparticles 
in cardiac myocytes and macrophages.  These particular cell types were chosen due to the 
susceptibility of the heart to nickel poisoning [139] and the phagocytic nature of immune 
cells, which engage these types of microspheres in vivo.  Both NTA-functionalized and 
NTA-Ni-functionalized microparticles showed similar levels of toxicity or better when 
compared to cells treated by non-modified PCADK microparticles for both cells lines.  
Previous work in our lab and others has established biocompatibility of PCADK 
microparticles in a variety of animal models with milligram doses being given to rats and 
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mice [135, 136, 140, 141].  Given that no increase in toxicity associated with the surface 
functionalization of these microparticles in vitro, safe use of these microparticles for in 
vivo applications is anticipated. 
 After establishing biocompatibility of the NTA-Ni system, we sought to show 
bioactivity in two potential applications for the non-covalent tethering of proteins.  First, 
we tested the bioactivity of tethered His-tagged VEGF to activate VEGFR2 with the 
particle directly in contact with cells or separated by a transwell membrane with 3 μm 
pores.  As expected, protein loaded onto the surface of the microparticle showed a dose 
dependent response when incubated directly on the cells, indicating the protein activity 
was still intact after complex formation.  In this case, VEGF loaded microparticles could 
have activated its receptor while still bound to the microparticle.  In order to separate the 
effects of tethered protein versus protein that has been released, we tested if VEGF 
release from microparticles could diffuse across a transwell insert.  Our data show that 
VEGFR2 phosphorylation was seen at 1, 2, and 3 hours but not as early as 20 minutes 
suggesting that some time was required for VEGF to be released from the surface of the 
microparticle and diffuse to the cell layer.  Furthermore, these data suggest that sustained 
activation occurs in the transwell system as VEGF signaling with free ligand is rapid 
[142]. 
 While proteins were released intact from the surface, experiments also 
demonstrated that targeting could be achieved using cell surface receptors; a greater than 
two-fold improvement in binding was observed with targeted particles.  VE-Cadherin 
acts as a cell-cell junction protein and is a potential target for endothelial cells due to its 
selective expression in vivo.  The targeting system presented here used a His-VE-
Cadherin/Fc chimera that greatly increased the size of the protein, thus reducing the 
density of targeting ligands on the surface of the microparticle.  Diffusion of the VE-
Cadherin away from the microparticle could have also played a role in the modest 
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targeting.  Furthermore, there was a strong potential for microparticles to interact with 
each other due to the homodimer formation between particles rather than exclusively with 
cells.  Despite these potential confounding variables, significant improvements in 
targeting were observed and generate enthusiasm for future targeting studies with unique 
ligands. 
 Surface modification of polyketal microparticles with IMAC chemistries show 
potential for improving the delivery of proteins with polymer microspheres.  We show 
here that the NTA-Ni complex is suitable for non-covalent tethering of proteins in their 
bioactive forms.  These proteins can be adapted for use as a therapeutic payload or as 
targeting ligands for smaller microparticles.  Many parameters of the system can 
potentially be tuned to control features such as release kinetics and warrant further 





EXTRACELLULAR DNA AS A PLATFORM FOR TARGETING 
NECROTIC TISSUE IN THE INFARCT 
5.1 Introduction 
 Traditional approaches to targeting therapeutics or drug delivery vehicles rely on 
identifying proteins that exist in a higher abundance in a particular organ.  Antibodies 
against these upregulated proteins are then conjugated to drug carriers in order to target 
delivery.  This strategy is potentially difficult for treating cardiac dysfunction due the 
lack of promising protein candidates that are specifically upregulated in the infarct 
following MI.  In addition, relying on antibodies as targeting ligands precludes drug 
delivery vehicles from remaining small and able to diffuse large distances due to the 
inherently large size of antibodies themselves (~150 kDa); the smallest functional unit of 
an antibody, the variable domain (Fv), is approximately 25 kDa [143].  Conjugation of 
the Fv fragment would double the size of most therapeutic proteins (e.g. cytokines) and 
increase the size of a small molecule drug by an order of magnitude or more.   
 Our approach to targeting infarcted tissue focuses on targeting extracellular DNA 
released by necrotic cells.  Necrotic cells should be abundant in the infarct due to the 
depletion of ATP downstream of the occlusion and accumulation of metabolic wastes 
during the ischemic phase of MI.  These conditions typically drive necrotic cell death, 
which comes with loss of cellular membrane integrity.  By contrast, controlled cell death 
(apoptosis) typically proceeds with no loss of membrane integrity and eventual 
phagocytosis of an apoptotic body without significant extracellular release of DNA.  
Apoptotic cell death dominates in healthy tissue homeostasis.  As a result, each cell that 
dies through the necrotic pathway should contribute on the order of picograms of DNA 
per cell.  Given that nearly ten million cells show compromised cell membranes in rat 
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models of myocardial infarction [144] (and on the order of billions of necrotic cells in 
humans suffering from MI), this represents a significant basis for targeting therapeutic 
molecules.   
  
Figure 5.1. A variety of Hoechst conjugates can be synthesized from Hoechst-amine.  Hoechst 33258 
is available commercially for use as a fluorescent stain for DNA.  Using commercial Hoechst as an 
inspiration, Hoechst with a short PEG linker and primary amine (Hoechst-amine) was synthesized, which 
allowed for further conjugation.  Thiol-reactive Hoechst conjugates (Hoechst-PEG-maleimide and Hoechst-
thiopyridiyl) can be used to modify cysteine residues on proteins using either permanent 
(maleimide/thioether bond) or reversible (thiopyridyl/disulfide bond) covalent linkages.  Hoechst-biotin can 
be used with a variety of streptavidin conjugates and is a highly sensitive probe due to the strong binding 
affinity between streptavidin and biotin.  Hoechst-IR786 is a near-infrared fluorescent dye conjugate that 




 DNA binding dyes, such as Hoechst, are excellent candidates for small molecule 
targeting ligands.  DNA binding dyes are inherently designed to have a high affinity for 
DNA, and typically have dissociation constants on the order of many antibody-antigen 
interactions.  Hoechst is also significantly smaller than antibodies with a molecular 
weight of 534 Da.  Furthermore, Hoechst has a history of being used in vivo both as a 
tracer for angiogenesis and as a chemotherapeutic in humans, which suggests that low 
doses are tolerated by the body.   
 This chapter will introduce the different Hoechst-conjugates that were synthesized 
and potential downstream applications.  All of the Hoechst conjugates used in these 
studies were based on Hoechst-amine (Figure 5.1).  The synthesis of this molecule was 
describe by Dasari, et al. [145] and served as the foundation for further ligation of 
Hoechst to other molecules.  Furthermore, the use of Hoechst-IR786 for imaging necrosis 
via near infrared fluorescence imaging will be highlighted.  Lastly, attempts to deliver the 
therapeutic proteins VEGF and SOD to the infarct following MI using Hoechst as a 
targeting agent will be discussed. 
 
5.2 Results 
Synthesis and Characterization of Hoechst-Conjugates 
 Hoechst-amine was synthesized as reported by Dasari, et al. [145].  A sulfhydryl-
reactive Hoechst derivative was synthesized using standard NHS-amine coupling 
chemistry (Figure 5.2).  Hoechst-PEG-maleimide was purified using preparative TLC 
and validated via 
1
H-NMR and mass spectrometry (Figure A.4-A.5, appendix).  
1
H-
NMR was analyzed for the inclusion of vinyl protons, indicative of the maleimide group 
(singlet, 6.77 ppm).  Mass spectrometry was conducted using matrix assisted laser 
desorption/ionization (MALDI-TOF) and showed a primary ion peak at 954.5, compared 
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to the calculated value of 954.1.  UV-absorbance spectra (200-400 nm) of commercially 
available Hoechst 33258, Hoechst-amine, and Hoechst-PEG-maleimide were collected 
using 200 µM solutions (Figure 5.3).  All three species had similar spectra with peaks 
occurring at 260 and 340 nm. 
 
Figure 5.2. Synthesis scheme for Hoechst-maleimide.  Hoechst-amine was reacted with N-
hydroxylsuccinimide-PEG4-maleimide in dimethlyformamide and triethylamine at room temperature 
overnight.  The reaction mixture was purified using preparative thin layer chromatography in order to 
isolate Hoechst-PEG-maleimide, which can be used to modify sulfhydryl groups on proteins. 
 
 
Figure 5.3. UV-Absorbance spectra of Hoechst species. UV spectra were recorded for three Hoechst 






























Cell permeability of Hoechst-Conjugates 
 Primary rat neonatal cardiac myocytes were used to determine the cell 
permeability of Hoechst species (Figure 5.4).  Cells were plated in multiwell plates and 
Hoechst compounds added to the media at a final concentration of 0.1 mg/ml.  
Fluorescence was measured over 24 hours and used as a measure of permeability as 
Hoechst compounds significantly increase quantum efficiency (fluorescence intensity) 
when bound to DNA, the increase in fluorescence can be attributed to compound binding 
to DNA in the nucleus.  Data were normalized to control cells treated with no dye set to 
unity.  Hoechst-amine treated cells showed similar increases in fluorescence when 
compared to commercial Hoechst (data not shown), with an eight fold increase in 
fluorescence after six hours.  By contrast, Hoechst-biotin did not appear to be cell 
permeable and had fluorescence intensities equivalent to control cells at 24 hours. 
 
Figure 5.4. Relative cell permeability of Hoechst-amine and Hoechst-biotin.  Hoechst conjugates have 
varying levels of cell permeability.  Rat neonatal cardiac myocytes were cultured in multiwell plates and 
blue fluorescence of the Hoechst was monitored over time.  Cells were incubated up to 24 hours with 0.1 
mg Hoechst compound/ml in serum free media.  Commercially available Hoechst and Hoechst-amine 
showed similar increases in fluorescence, despite the addition of three ethylene glycol units and a primary 
amine.  Biotinylated Hoechst, which was linked to biotin with a 15-unit PEG chain, showed low levels of 




























Figure 5.5. In vivo testing of Hoechst-biotin in an rat MI model of necrosis.  Rats were subjected to 
ischemia-reperfusion (IR) surgery in the heart.  One day after ischemia-reperfusion surgery, 500 μg of 
Hoechst-biotin was injected intravenously and allowed to circulate for one hour.  Frozen sections of the 
heart were examined using confocal microscopy.  Tissue morphology was examined via red 
autofluorescence of the tissue.  Sham operated animals showed cell membrane integrity in the left ventricle 
(LV) and little blue fluorescence (Hoechst).  IR-operated animals showed necrosis in the LV and diffuse 
blue staining suggesting release of DNA from necrotic cells. 
 
 In vivo permeability was tested in a rat model of myocardial infarction.  Rats were 
subjected to thirty minutes of ischemia followed by reperfusion surgeries (IR surgeries) 
and allowed to recover for a day.  Twenty-four hours post-surgery, 0.5 mg of Hoechst-
biotin was administered intravenously via retro orbital injection.   The compound was 
allowed to circulate for one hour before the rat was sacrificed and heart embedded in 
OCT resin for cryosectioning.  Sections were mounted and imaged using confocal 
microscopy without any additional staining (Figure 5.5).  Sham operated animals showed 
very low blue fluorescence indicative of Hoechst-DNA.  In particular, no nuclei were 
stained blue.  Autofluorescence was used to examine tissue morphology (red), which 






that received IR-surgery, on the other hand, had significant diffuse blue staining, 
indicating extracellular DNA, and no focal staining of nuclei.  Tissue autofluorescence 
suggested that cell membranes were compromised. 
Near Infrared Imaging of Necrosis with Ho-IR786 
 Near infrared fluorescence imaging is commonly used for imaging live animals or 
whole organs.  The optical properties of most tissues allow good penetration depths, on 
the order of millimeters to centimeters, of near infrared wavelengths.  Hoechst was 
conjugated to the near infrared fluorescent dye 2-[2-[2-Chloro-3-[(1,3-dihydro-1,3,3-
trimethyl-2H-indol-2-ylidene)ethylidene]-1-cyclohexen-1-yl]ethenyl]-1,3,3- 
       IR786                                         Hoechst-IR786 
    
Figure 5.6. Near-infrared fluorescence image of organs from animal injected with IR-786 or Ho-
IR786.  Mice were subjected to IR-surgery and organs were harvested after administering 10 nanomoles of 
IR786 (a-d) or Ho-IR786 (e-f) intravenously.  IR786 treated animals showed higher fluorescence intensities 
than Ho-IR786, with peak values reaching 6919 RFU compared to 2244 RFU.  Both treatments showed 
significant accumulation in the liver.  (a & e) Brightfield/near infrared merge, (b & f) brightfield, (c & g) 


















trimethylindolium iodide (IR786) in order to have an extracellular-DNA-specific 
fluorescent probe to visualize necrosis in the heart. 
 Mice were subjected to thirty minute IR-surgery and injected with ten nanomoles 
(100 µl of 100µM dye in 5% ethanol, 5% Cremophor EL, 90% PBS) of dye (either 
Hoechst-IR786 or IR786) two hours after surgery.  Dye was injected intravenously via 
retro orbital injection.  Animals were sacrificed twenty minutes post-injection and 
perfused with saline to wash out any unbound dye.  After three minutes of saline 
perfusion, tissue was fixed by perfusion of 4% paraformaldehyde in PBS.   Animals that 
were injected with unmodified IR-786 showed significant near-infrared fluorescence in 
all organs (Figure 5.6).  Animals that received Hoechst-IR786 showed high levels of dye 
in the liver.  But compared to IR786-treated animals, fluorescence intensity was 
significantly lower, peaking at 2244 RFU for Hoechst-IR786 compared to 6919 RFU for 
IR786. 
 To better quantify fluorescence, hearts were imaged separately at a higher 
magnification (Figure 5.7).  Animals that received Hoechst-IR786, regardless of surgery 
type, showed some elevation in near-infrared fluorescence compared to uninjected 
control animals.  Mean fluorescence intensity for the infarcted area was quantified using 
ImageJ and normalized to sham operated hearts.  Comparison between sham operated 
and IR-surgery demonstrated significant increase in Hoechst-IR786 fluorescence in the 
left ventricle when injected two hours post-surgery (n=3, * p < 0.05).  Animals that were 
injected 24 hours after surgery showed slight elevation in fluorescence intensity for IR-
operated animals compared to sham, but did not reach statistical significance.  Additional 
imaging of animals that received IR-surgery (Figure 5.7c-d) showed near-infrared 
intensity concentrated in the left ventricle free wall.  Figure 5.7c illustrates that the 
suture, which was left in the heart and is visualized by the decreased intensity running 






Figure 5.7. Ho-IR786 targets the left ventricle of mice that receive ischemia-reperfusion surgery.  (a) 
Comparison of three hearts, IR-surgery, sham operated, and uninjected control under NIR fluorescence 
imaging.  (b) Mice were subjected to sham or IR-surgery and injected with 10 nmol Hoechst-IR786 at 
different time points.  Animals were sacrificed one hour after injection, perfused, and organs harvest for 
imaging.  Semi-quantitative analysis shows time dependence for NIR intensity. (n=3, * p < 0.05 compared 
to sham, Student’s t-test)  (c) Zoom of IR-surgery heart that received Hoechst-IR786.  Suture remains 
visible with high NIR fluorescence intensity downstream. (d) Thick section of heart that received IR-










































of an IR-operated heart (Figure 5.7d) shows that the fluorescence intensity is greater in 
the left ventricle compared to the right ventricle. 
Hoechst Conjugates of Therapeutic Proteins 
 VEGF was expressed as previously described [146] and contained unpaired 
cysteine residues.  These residues were targeted for modification using Hoechst-PEG-
maleimide and reacted with ten equivalents of the Hoechst compound according to the 
scheme in Figure A.6 (appendix).  Mice were subjected to IR surgery described above.  
Two hours following IR-surgery, two micrograms of VEGF or HoVEGF was injected 
(100 µl injection volume) intravenously via retro orbital injection.  The mouse was then 
sacrificed and perfused for three minutes with normal saline.  The heart was dissected 
into three pieces: left ventricle free wall (LV), right ventricle free wall (RV), and 
remaining part (termed “heart” in subsequent figures).  These pieces were homogenized 
in RIPA buffer and analyzed for VEGF content via ELISA. 
 Animals that received either VEGF or HoVEGF injections had higher levels of 
VEGF compared to uninjected control mice that had received IR-surgery, with the 
HoVEGF group trending higher (Figure 5.8).  Animals that received HoVEGF injection 
had 47±12 pg VEGF/mg protein in the LV and lower amounts in the heart and RV (27±7 
pg VEGF/mg protein and 32±8 pg VEGF/mg protein, respectively).  VEGF injected 
animals had less disparity between heart sections with 34±7, 24±5, and 27±7 pg 
VEGF/mg protein in the LV, heart, and RV, respectively.  Injected IR controls had 11±7, 
2±1, and 13±9pg VEGF/mg protein in the LV, heart, and RV, respectively.  Levels of 
HoVEGF were significantly higher than IR animals when analyzed using t-test, but did 
not achieve significance through ANOVA (p=0.06).  No other treatments were 
significant.  Amounts of VEGF recovered maximally accounted for less than 1% of the 




Figure 5.8. Levels of modified and unmodified VEGF in the heart post-IR.  Mice were subjected to 
thirty minutes of ischemia followed by reperfusion.  Two hours after surgery, two micrograms of either 
VEGF or HoVEGF was injected intravenously.  The mouse was then sacrificed fifteen minutes after 
injection and perfused to wash away unbound VEGF.  The heart was sectioned into the LV free wall, RV 
free wall, and the rest of the organ, termed “heart” in these graphs.  Tissue pieces were homogenized and 
tested for VEGF levels via ELISA. (mean±SEM, n≥6, *p < 0.05 compared to IR control, ANOVA followed 
by Tukey-Kramer post test) 
 
 To determine if antioxidant enzymes could be delivered in this manner, SOD 
protein was modified with Hoechst according to the scheme in Figure A.7 (appendix).  
Stock SOD contained no detectable sulfhydryl groups using Ellman’s assay and had an 
activity of 3619 U/mg.  Following reaction with 20 equivalents of Traut’s reagent (2-
iminothiolane, which produces free sulfhydryls upon reacting with amine groups), SOD 
molecules had an average of 12.5 sulfhydryl groups and activity of 3163 U/mg.  
Thiolated-SOD was then reacted with Hoechst-PEG-maleimide (two equivalents, with 
respect to –SH) overnight to produce Hoechst-SOD (HoSOD).  No detectable sulfhydryls 
were present using Ellman’s assay and protein activity decreased to 1057 U/mg.  The 


























of twelve Hoechst ligands. Mass spectrometry show that protein molecular weight was 
increased after reacting with Hoechst-PEG-maleimide (Figure 5.9). 
 
 
Figure 5.9. Mass spectra for SOD and HoSOD.  Mass spectra were collected using MALDI-TOF.  (a) 
Unmodified showed sharp peaks at 15.6 kDa, 31.3 kDa (native protein), 47.0 kDa, and 63.4 kDa.  (b) 
HoSOD, by contrast had heavier peaks, but also peaks that had shoulders with higher molecular weights, 
suggesting different number of Hoechst ligations.  Peaks were found at 16.2 kDa, 32.6, kDa, 50.0 kDa, and 
65.0 kDa. 
 
 HoSOD was tested in the same mouse model of IR, as described above.  These 
studies were similar to the HoVEGF procedure with a thirty minute ischemic period and 
injection HoSOD two hours after surgery.  Two hundred units of either free SOD or 
HoSOD were injected intravenously and the animal sacrificed 15 minutes following 
injection.  Animals were perfused with PBS for three minutes before organs harvested 
and dissected as described previously.  Tissue homogenates were analyzed for SOD 
activity and normalized to protein concentration (Figure 5.10).  HoSOD was 
significantly higher than control in all three heart sections, and significantly greater in the 
septal wall and remain heart piece following free wall dissection compared to SOD 
treatment (p<0.05).  SOD injected animals had significantly more activity in the LV, but 





































for 36 U of SOD activity in the LV, after subtracting endogenous SOD activity.  This 
would account for 18% of the initial injected dose. 
 
Figure 5.10. SOD activity in the heart fifteen minutes following administration of SOD and HoSOD. 
Mice were subjected to IR-surgery.  Two hours following surgery, 200 U of SOD or HoSOD was injected 
intravenously.  Mice were sacrificed and perfused fifteen minutes post-injection.  The heart was dissected 
and homogenized and analyzed for SOD activity.  SOD activity was elevated for both SOD and HoSOD 
injected animals in all fractions. (mean ± SEM, n≥5, *p < 0.05 compared to IR, # p>0.05 compared to 
SOD, ANOVA followed by Tukey-Kramer post test) 
 
 The study was repeated using a higher dose (400 U) and longer time between 
injection and sacrifice (one hour).  Figure 5.11 illustrates that all three groups had similar 
levels of SOD activity (2-3 U/mg protein) under these conditions.  Western blot analysis 





























Figure 5.11. SOD activity in the heart one hour following administration of SOD and HoSOD.  Mice 
were subjected to IR-surgery.  Two hours following surgery, 400 U of SOD or HoSOD was injected 
intravenously.  Mice were sacrificed and perfused one hour post-injection.  The heart was dissected and 
homogenized and analyzed for SOD activity.  SOD activity, regardless of treatment or heart fraction, 
ranged from 2-3 U/mg protein. (mean ± SEM, n≥3, no statistical significance found) 
 
5.3 Discussion 
 The overall goal for this aim was to examine the feasibility of using extracellular 
DNA as a targeting platform for the infarction in the heart following MI.  Anoxic 
conditions during MI generate necrotic lesions in the heart with high concentrations of 
extracellular DNA.  While the necrotic lesion does not represent tissue that can be 
salvaged, the specific localization of extracellular DNA to the infarct can serve as a 
targeting platform and reservoir for delivering drugs to the border zone surrounding the 
infarct core, where cells are still salvageable.  Furthermore, this aim is a departure from 
traditional drug targeting strategies that focus on the use of antibodies and highlight the 
potential for using small molecules with high binding affinities as targeting ligands.  By 
using small molecule targeting ligands, molecular weights of therapeutics can remain 
low, especially compared to the 150 kDa that antibody conjugation would add, and thus 






















 Hoechst is widely used in research settings to stain the nuclei of cells in histology 
and flow cytometry.  Commercial Hoechst is cell permeable has a high binding affinity 
for the minor groove of DNA, particular in regions that are A-T rich.  Upon studying the 
crystal structures of Hoechst-DNA complexes, it became clear that the phenolic hydroxyl 
was a candidate site for modifying the compound with little risk of negatively affecting 
binding affinity to DNA.  Using Hoechst as a basis, Hoechst-amine was designed to have 
a short PEG linker with a primary amine at the phenolic hydroxyl site (Figure 5.1).  The 
PEG linker was added to modulate cell permeability while the primary amine allowed for 
further conjugation to other molecules.  Unfortunately, direct modification of this 
phenolic hydroxyl was not possible and Hoechst-amine was synthesized in using the 11-
step route shown in Figures A.1-A.4 (appendix), and verified via mass spectrometry and 
1
H-NMR (data not shown). 
 A thiol-reactive version of Hoechst was synthesized using NHS-PEG4-Maleimide, 
under standard NHS-chemistry linking conditions (dimethyl formamide with 
triethylamine, overnight at room temperature).  The compound was purified using 
preparative thin layer chromatography and verified using mass spectrometry and 
1
H-
NMR (Figures A.4-A.5, appendix).  Hoechst-PEG-maleimide allows the site-specific 
modification of proteins by targeting unpaired cysteine residues.  Alternatively, primary 
amine residues on a protein can be modified using Traut’s reagent, which converts 
amines to sulfhydryls, and subsequently modified using the maleimide conjugate.  One 
beneficial property of using Hoechst is that it has well characterized spectral properties.  
In order to ensure that optical properties were not adversely affected, absorbance spectra 
were generated for Hoechst-amine and Hoechst-PEG-maleimide and compared with 
commercially purchased Hoechst 33258 (Figure 5.3).  Both pathways were utilized to 
functionalize therapeutically relevant proteins, and are discussed later in this chapter. 
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 Hoechst-biotin was one of the earlier conjugates synthesized in order to test proof 
of concept.  This compound was designed to be cell impermeable due to its 15-PEG 
linker and have a high sensitivity mechanism for detection (biotin-streptavidin 
interaction).  In vitro cell permeability studies using primary neonatal cardiac myocytes 
(Figure 5.4) and took advantage of the fact that Hoechst compounds are not highly 
fluorescent unless bound to DNA; by binding in the minor groove of DNA, vibrational 
and rotational modes are significantly reduced, significantly increasing the fluorescent 
quantum efficiency of the molecule.  It was expected that both Hoechst-amine and 
Hoechst-biotin would have similar cell permeabilities; Hoechst-amine contains a 3-PEG 
linker and a very hydrophilic primary amine, whereas Hoechst-biotin had a similarly 
hydrophilic 12-PEG linker.  Hoechst-amine showed similar increases in fluorescence 
when compared to commercially available Hoechst.  Hoechst-biotin, on the other hand, 
behaved as expected and had fluorescence intensities on par with basal fluorescence of 
untreated cells. 
 This result prompted us to test the Hoechst-biotin molecule in vivo using a rat 
model of MI.  Under confocal microscopy, extracellular DNA was visualized directly 
(Figure 5.5).  The high autofluorescence of cardiac tissue provided a way to visualize 
cell morphology; sham operated animals had healthy tissue morphology, whereas rats 
that received IR surgery had increased interstitial spaces between cells.  More 
importantly, sham operated animals had very low levels of blue fluorescence, indicative 
of low binding of Hoechst-biotin to DNA.  In particular, cell nuclei were not labeled blue 
by the Hoechst-biotin suggesting that the compound was not cell permeable in vivo.  
Furthermore, data provided by the IR operated rats showed significant blue fluorescence 
in the interstitial spaces between cells.  This is consistent with the hypothesis that 
necrotic cell death generates significant extracellular DNA.   
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 However, an alternative explanation that Hoechst compounds may have some 
non-specific interactions with cellular components exposed due to necrosis.  Hoechst 
contains three planar, aromatic groups that could interact with hydrophobic pockets of 
proteins or other molecules.  However, these interactions may not increase the 
fluorescence intensity, as is seen with DNA minor groove binding, and likely occur with 
very low affinity in vivo.  Furthermore, preliminary experiments using cells fixed in 
methanol, which would allow access to all intracellular components, demonstrated that 
blue fluorescence was only seen in the nuclei.  This suggests that the blue signal is 
specific to DNA binding, but that additional experiments using DNase or other treatments 
are needed to rule out non-specific Hoechst-binding. 
 In order to further examine the possibility for targeting extracellular DNA in the 
infarct, Hoechst-IR786 was synthesized [145].  This molecule consists of a 10-PEG 
linker and the near-infrared fluorescent dye IR786.  Near infrared imaging allows for 
imaging of live animals and whole organs due to low tissue attenuation of near-infrared 
wavelengths by tissue.  As an initial control, unmodified IR786 was injected 
intravenously into a mouse and compared to Hoechst-IR786 (Figures 5.6).  In both cases, 
the liver showed significant enrichment of the dye.  We hypothesize that the dye is likely 
metabolically cleared from the body through the liver.  In addition, there have been 
reports of IR786 binding to albumin [147], which would also support a hepatic clearance 
route.  In the case of unmodified IR786, high concentrations were also seen in the lungs.  
This enrichment may be due to a first pass effect; since the dye was injected 
intravenously, the lungs represent the first capillary bed where it could partition into cell 
membranes as it passed through the cardiopulmonary circulation.  However, the main 
difference between compounds was the magnitude of fluorescence intensity.  While the 
heat maps in Figures 5.6 appear similar qualitatively, unmodified IR786 had 
significantly higher intensities (heat map scale: 1896-6919) compared to Hoechst-IR786 
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(heat map scale: 1933-2244).  This suggests that the increased water solubility and 
decreased cell permeability resulted in less nonspecific tissue binding of the Hoechst 
conjugate. 
 We examined the distribution of Hoechst-IR 786 in the heart tissue following IR.  
By increasing magnification the differences in the distribution of the compound in the 
hearts of sham and ischemia-reperfusion operated mice could be compared quantitatively.  
Figure 5.7a demonstrates that there was a basal increase in heart fluorescence due to the 
Hoechst-IR786, as both sham and ischemia-reperfusion operated animals had higher 
fluorescence intensities compared to a control heart that did not receive any dye.  
However, distinct regional differences are seen between sham and ischemia-reperfusion 
operated animals.  Indeed, upon closer examination of ischemia-reperfusion operated 
hearts, there is a distinct zone that would correspond with the infarcted area.  Figure 5.7c 
shows another heart where the suture has been left in place with high fluorescence 
directly downstream of the ligation.  Thick cross-sections of the heart (Figure 5.7d) 
showed localization of the compound in the left ventricle free wall and not the right 
ventricle.  These data are consistent with where one would expect necrotic cell death to 
occur and correlate with commonly seen triphenyltetrazolium chloride (TTC) staining of 
infarcted myocardium [148]. 
 Semi-quantitative data generated by measuring fluorescence intensities of the 
images showed dependence between IR786 enrichment and the time between injection 
and ischemia-reperfusion (Figure 5.7b).  Animals that were injected soon after surgery 
(two hours) had greater differences between ischemia-reperfusion and sham compared to 
mice that were injected the following day.  This finding did not fully agree with 
previously published literature, as other groups have measured the onset of necrosis at 
later time points in different animal models of myocardial infarction.  A study conducted 
by Kajstura, et al. injected rats with anti-myosin antibody prior to permanent LAD 
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ligation in order to probe cell membrane integrity post-infarction.  This study 
demonstrated that approximately 100,000 cells were positive for the anti-myosin 
antibody from 2-4.5 hours post occlusion.  The number of cells with compromised 
membranes increased to three million cells at six hours.  These numbers held steady up to 
48 hours post infarction, and cells with compromised membranes are nearly absent by 
seven days.  However, the authors acknowledged that the large size of the anti-myosin 
antibody may have caused an underestimate of the extent of necrosis at early time points 
[144].  In a similar study validating the use of TTC staining in a permanent occlusion 
model of MI in rats, Vivaldi, et al. demonstrated irreversible tissue damage after thirty 
minutes of occlusion (as measured by TTC staining and validated by electron 
microscopy), but that the infarct matured over the course of six hours after occlusion and 
persisted for at least two days after injury [149].  Data generated with Hoechst-IR786 are 
in line with previous studies in that we were able to detected evidence of irreversible cell 
death two hours after injury.  However, previous work using other markers of tissue 
damage (i.e. staining for myosin components or absence of dehydrogenase enzymes) 
have observed early irreversible cell death, but suggest that this persists for days post-
infarction.  Yet, animals injected with Hoechst-IR786 one day post-infarction did not 
show a significant increase in near infrared fluorescence.   
 DNA and proteins are cleared and recycled by the body through different 
mechanisms.  This, coupled with differences in surgical models of MI, may have played a 
role in the differences seen between DNA and protein markers of necrosis.  Extracellular 
DNA is cleared rapidly from the body via endogenous DNase expression.  Results from 
Naperei, et al. demonstrate that application of serum to cells undergoing necrosis in vitro 
clear high molecular weight chromatin DNA by 24 hours [150].  Furthermore, naked 
DNA injected intravenously into rats has been demonstrated to be cleared from the serum 
with over 95% cleared in the first five minutes following injection [89].  Given these 
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data, one would expect DNA to be cleared from the infarct rapidly compared to other 
necrotic markers. 
 Since the presence of DNA is required for the Hoechst targeting strategy, 
subsequent studies involving therapeutic proteins focused on the two hour post-surgery 
time point established by the near infrared imaging studies.  Given the limited window of 
opportunity for targeting the infarct via extracellular DNA, it was important to use 
therapeutics that could blunt the initial damage following reperfusion.  Two candidate 
proteins were identified: VEGF for neovascularization of the infarct and SOD to blunt the 
initial surge of oxidative stress that comes with reperfusion of the heart.   
 As necrotic tissue is not salvageable, it is important that the therapeutic proteins 
have a mechanism to either have an effect on viable tissue from a distance or be able to 
be released from the necrotic tissue so that it can be transported to viable cells.  The 
chemical conjugation techniques used for both VEGF and SOD modification generated a 
stable thioether bond.  The rationale behind using this chemistry was that it would allow 
for better demonstration of targeting compounds to the infarct since clearance from the 
necrotic tissue would be diminished.  However, it is possible to engineer more labile 
bonds, such as disulfides or ester linkages, which can cleave under physiological 
conditions (i.e. redox potential, hydrolysis, or enzymatic cleavage).  Furthermore, given 
that necrosis incites significant inflammation and is cleared by leukocytes, it is expected 
that DNA degradation and clearance play a larger role in the release of Hoechst-
conjugated therapeutics.  Once liberated from extracellular DNA, Hoechst compounds 
could then be carried away from necrotic tissue through a combination of diffusive and 
convective transport.  Given that the animal model used in these studies relied on 
ischemia-reperfusion surgeries, convection was likely the dominant transport factor. 
 VEGF is a potential therapeutic candidate for this strategy as it is a central 
regulator of blood vessel growth.  During the ischemic period in MI, blood vessels can be 
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lost, along with the cardiac tissue.  As a result, even after reestablishment of blood flow 
in the larger vessels, there may be regions of poor reperfusion.  This may be detrimental 
for stunned myocardium that will eventually die due to insufficient nutrient transport.  
Neovascularization may be able to maintain or rescue some heart function following MI.  
VEGF therapy is by no means a curative as vessel growth is slow and requires other 
factors, such as PDGF, to stabilize growth.  However, it is a logical choice for targeting 
in the acute phase following MI, as it is the first signal that leads to capillary sprouting in 
tissue and could help in the development of collateral vessels to salvage at risk 
myocardium.  Furthermore, by using the necrotic core as a reservoir, it may be possible to 
establish a gradient of VEGF in the infarct; as VEGF is liberated from extracellular 
DNA, it can be transported to the surrounding vasculature via convection and diffusion 
where it can act on distal endothelial cells.  Other groups have established the importance 
of mitogen gradients and concentrations as they relate to cell polarity and proliferation, 
respectively [151]. 
 VEGF was expressed with a terminal, unpaired cysteine as previously described 
[146] allowing for site-specific modification.  This is important since many cytokines and 
growth factors are highly dependent on shape in order to bind and activate their 
complimentary receptors.  The added cysteine residue was modified previously and 
shown to retain bioactivity.  The disadvantage for modifying this route was that a 
maximum of two Hoechst moieties per active cytokine is possible (VEGF is a native 
dimer and was expressed such that each subunit contained one unpaired cysteine).  
Characterization of HoVEGF was difficult since such small amounts of protein at low 
concentrations were used.  These concentrations were not suitable for mass spectrometry 
analysis or Ellman’s assay for free sulfhydryl determination. 
 Ischemia reperfusion surgeries were conducted in mice in order to test the ability 
of Hoechst targeting to enrich the growth factor in the infarct.  Quantification of VEGF 
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via ELISA showed that there was trend of higher levels of HoVEGF than VEGF in the 
left ventricle free wall (47 pg VEGF/mg protein compared to 34 pg/mg) (Figure 5.8).  
This trend held for the other sections of the heart analyzed, the right ventricle free wall, 
and the rest of the ventricle (mostly the septum and parts of the apex, termed “heart” in 
the figures).  However, while there was a trend for more HoVEGF enrichment compared 
to VEGF, the levels that were recovered from the heart were not significant; the levels of 
HoVEGF recovered in the left ventricle account for less than one percent of the total 
injected dose (2 µg).  One of the potential issues that may explain this finding is that 
HoVEGF may be binding elsewhere in the circulation due to the abundance of VEGF 
receptors throughout the circulation.  Given that the binding affinities between VEGF and 
its receptor and Hoechst and DNA are on the same order of magnitude, there is not a 
strong likelihood that HoVEGF is enriched in the heart based on the large number of 
VEGF receptors in the vasculature. 
 The second candidate protein was selected to avoid the issue of binding to 
receptors while still having some potential therapeutic benefits.  As described earlier, 
oxidative stress plays a large role in cardiac dysfunction and superoxide radicals are 
central to the progression of heart failure.  Superoxide therapy has shown to be beneficial 
for cardiac function in other studies if given in high doses acutely following MI.  SOD 
that is immobilized in the necrotic core may have a limited effect on the levels of 
extracellular ROS in the viable border zone, but given the high reactivity of these 
radicals, SOD therapy would be optimal directly in the border zone.  Furthermore, given 
that it is not a cytokine, SOD is not expected to have any other competing high-affinity 
interactions in vivo. 
 From a synthetic point of view, it was also possible to work with larger quantities 
of SOD, which allowed more thorough characterization of the protein conjugates.  
Reactions involving SOD were conducted on the milligram scale, rather than the 
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microgram scale, as was done with VEGF.  Ellman’s reagent was used to track the 
average number of sulfhydryls per molecule.  Ligation of Hoechst moieties was validated 
through the disappearance of sulfhydryls.  The Hoechst-PEG-maleimide conjugate was 
used over the Hoechst-thiopyridyl conjugate since maleimides react to form thioether 
bonds, which are not redox-sensitive.  The disulfide bond produced by the thiopyridyl 
coupling can be reduced, liberating the protein from the Hoechst ligand.  Modification of 
SOD was also validated by mass spectrometry (Figure 5.9).  These data indicate that 
there was both a shift in the most abundant ion peaks as well as an appearance of a 
shoulder containing higher m/z species (i.e. higher molecular weights indicative of 
conjugated the 954 Da Hoechst-PEG-maleimide group). 
 Results shown in Figure 5.10 suggest that greater superoxide scavenging activity 
is seen with animals injected with HoSOD in all three heart sections.  While this is 
promising, the fact that unmodified SOD also elevated superoxide scavenging activity in 
the tissue suggests that fifteen minutes may not be sufficient time to wash away non-
specifically bound protein.  This was surprising given that each mouse was perfused 
immediately following sacrifice in order to remove any HoSOD or SOD that remained in 
the blood.  Moreover, no strong LV versus RV localization suggests a DNA-independent 
binding mechanism.  The amount SOD activity in the left ventricle maximally amounted 
to 10% of the initial injected dose and did not appear to be specific to the areas where 
necrosis was expected; SOD activity was elevated in all sections of the heart compared to 
non-injected control animals that received IR-surgery. 
 The experiment was repeated with twice the dose (400 U) and longer time 
between injection and sacrifice (one hour).  In this case, there were no differences 
between the treatment groups in all heart sections (Figure 5.11).  This suggests that most 
of the injected protein was cleared from the tissue within the hour following injection.  It 
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is possible that the DNA is concurrently cleared from the necrotic tissue by DNases, 
reducing the amount of extracellular DNA available for targeting. 
 The studies involving therapeutic proteins had several limitations stemming from 
the surgical conditions used in the animal models.  Previous studies examining the time 
course of necrosis post-MI typically utilized permanent exclusion models of MI.  
Ischemia-reperfusion surgeries do not achieve the same levels of anoxia and may not 
produce similar levels of tissue necrosis.  However, IR-surgeries were used in these 
studies since they are more clinically relevant models of MI.  In addition, there was some 
concern that permanent occlusion models may not provide enough access to the necrotic 
core for Hoechst compounds; permanent occlusion models would rely on diffusion from 
collateral circulation or transmural diffusion.  It is possible that a thirty minute of 
ischemia was not ideal for creating a significant region of necrosis; work by DeBoer, et 
al. using a canine model of MI suggest 120 minutes of total occlusion are required to 
obtain greater that 95% necrosis in the infarct [152].   
 Another key factor that needs to be explored is the issue of timing after MI.  
Given the differences in techniques used to monitor necrosis post-MI, there was no 
significant body of literature describing extracellular DNA in the heart after injury.  It is 
possible that both the timing of the injections and animal sacrifice post injection may not 
have been ideal. The studies using therapeutic Hoechst-conjugates were designed based 
on the results from the Hoechst-IR786 study, which suggested that extracellular DNA 
was present at two hours but diminished at 24 hours.  A more intermediate time, such as 
six hours, would be an interesting time point to study as previously cited work by other 
groups indicate maturation of the necrotic lesion at this time point.  The amount of time 
between injection and animal sacrifice also plays a significant role in detecting infarct-
specific targeting.  Acute (fifteen minutes) time points were used in this work in order to 
minimize the amount of protein lost to natural clearance mechanisms.  As demonstrated 
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by the SOD data, waiting an hour after injection returned SOD activity levels to basal 
levels.  This suggests that SOD may have been degraded or inactivated by other pathways 
in the heart.  Significant work by others has examined strategies such as PEGylation in 
order to improve circulation half life of proteins, which may play a role in designing 
targeted protein therapeutics. 
 These data demonstrate that Hoechst-conjugates with a variety of functionality 
can be synthesized.  By tailoring the PEG-linker length, Hoechst-conjugates can be 
rendered impermeable to cell membranes.  This factor is critical in avoiding potential side 
effects, such as Hoechst inhibiting DNA helicase in healthy cells.  Near infrared imaging 
showed that Hoechst-based imaging probes show some promise for labeling extracellular 
DNA in necrotic tissue.  Other imaging modalities may benefit from Hoechst probes.  
The data using therapeutic proteins were disappointing, but raised several considerations 
for Hoechst-therapeutics.  Delivering proteins with high affinity interactions with other 
targets in vivo may pose some issues due to off target binding.  Given that VEGF-
VEGFR2 binding affinity is in the nanomolar range [153], HoVEGF likely bound to 
VEGF receptors in the circulation rather than enriching in the infarct.  Furthermore, small 
molecules may enrich in the infarct to a higher degree due to increased diffusivity.  
Future work may focus on developing therapeutic small molecule conjugates and will be 




SUMMARY AND FUTURE DIRECTIONS 
 
 The work included in this dissertation demonstrates three different drug delivery 
strategies that are uniquely tailored to overcome the obstacles of cardiac drug delivery.   
6.1 Polyketal Microsphere Formulations 
 Chapter 3 describes how changing polymer chemistry of microparticle drug 
delivery formulations can lead to a positive outcome in a permanent occlusion model of 
MI in rats.  In this aim, the p38 MAPK was inhibited using a small molecule drug for at 
least a week in vivo through a single intramyocardial injection of a sustained release 
microparticle formulation.  Other studies conducted with similar inhibitors required 
multiple daily doses to achieve comparable effects [112-114].  This approach can 
potentially be dangerous due to off-target side effects or lack of patient compliance, and 
more costly in terms of the amount of drug delivered.  The PCADK microparticle 
formulation was able to successfully improve cardiac function with a single injection 
whereas the current state of the art, PLGA microparticles, did not have a positive effect.  
The study demonstrated that PCADK microspheres showed decreased collagen 
deposition three weeks post-infarction.  The inhibition of fibrosis translated to an 
improvement in cardiac function between days seven and 21. 
 Several factors may have played a role in this finding.  Release kinetics in vivo 
may have played a role as endogenous esterases may accelerate PLGA release profiles.  
Degradation products also likely played a role; PCADK degrades into acetone and 1,4-
cyclohexane dimethanol.  Both products are non-toxic and lack acid moieties that could 
lower the pH and inflame the local microenvironment.  This is a significant advantage 
that is unique to polyketals amongst other degradable polymer systems.  Since the 
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publication of the p38 MAPK inhibitor study in Nature Materials in 2008 [135], the 
Davis and Murthy groups and others have shown similar results with various therapeutics 
and disease models. 
 Seshadri, et al. delivered the antioxidant protein superoxide dismutase (SOD) to 
an ischemia-reperfusion model of MI using PCADK microspheres [141].  Delivering 
SOD to the myocardium using PCADK microparticles had the advantage of sustained 
release as well as the ability to scavenge both intra- and extra-cellular superoxide.  
Parenteral delivery of SOD does not cross the cell membrane and is limited to scavenging 
extracellular superoxide.  Microparticle formulations were internalized by inflammatory 
cells, the key generator of radical oxidants, and scavenge superoxide before it is released 
into the tissue.  This contributed to a four-fold reduction in cardiac myocyte apoptosis 
compared to IR-surgeries alone, which was comparable to sham levels of apoptosis.  As a 
result, at three days post-infarction, animals treated with SOD-loaded polyketal 
microparticles (PK-SOD) had significantly better fractional shortening values compared 
to untreated animals.  However, at 21-days post-infarction, this initial improvement in 
cardiac function was lost and there was no statistical significance between IR-surgery 
alone and PK-SOD groups despite a 30% difference in the change in fractional 
shortening from baseline.  However, using a second therapy to target chronic 
inflammation (PK-p38i microparticles) had some additive effects as animals that were 
treated with both PK-SOD and PK-p38i did achieve statistically significant improved 
cardiac function compared to untreated animals, suggesting that SOD therapy is not a 
“magic bullet” and that multiple therapies delivered in concert are needed to prevent 
cardiac dysfunction. 
 Polyketals have been used to treat animal models of liver and lung inflammations.  
In both example a faster hydrolyzing copolymer of 1,4-cyclohexane dimethanol and 1,5-
pentanediol (PK3) were used in microparticle formulations.  Yang, et al. delivered the 
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anti-inflammatory drug imatinib (Gleevec, Novartis) encapsulated in PK3 microspheres 
in an acute liver failure model [136].  The PK3 microsphere formulation with the drug to 
significantly reduce serum levels of alanine aminotransaminase, a clinical marker of liver 
failure, through intravenous injection of PK3 microparticles.  Lee, et al. also 
demonstrated improved liver function in a mouse model of liver inflammation by 
delivering anti-TNF-α siRNA encapsulated in polyketal microparticles in vivo [140].  
Finally, Fiore, et al. showed that PK3 microparticles were biocompatible for pulmonary 
drug delivery and that formulations could deliver SOD to prevent lung fibrosis in 
response to bleomycin challenge [154]. 
 Numerous projects could be initiated using polyketals microparticles for various 
inflammatory diseases with different drugs, as is highlighted above.  In the cardiovascular 
space, ongoing work in the Davis laboratory is investigating using polyketal 
microparticles to deliver other therapeutics to the heart.  In one project, siRNA is being 
encapsulated using an ion-pairing method to reduce levels of enzymatic proteins that 
produce ROS.  This work will hopefully show beneficial effects of blunting the levels of 
ROS in the heart for the first time using siRNA-polymer therapy for cardiac dysfunction. 
There is also continuing work with SB239063 microparticles to better understand the 
pharmacokinetics and mechanism of action in vivo.  Collaborations are ongoing with 
other laboratories to investigate the potential for using polyketal microparticles to 
reprogram adult somatic cells into induced pluripotent stem cells by delivering 
transcription factors via polyketal nanoparticles. 
 While different permutations of treating inflammatory diseases with different 
therapeutics can be generated, polyketal technology would greatly be advanced by a 
systematic study investigating the effects of reaction conditions on polymer molecular 
weight.  One of the key issues with polyketal technology today is low molecular weight.  
Increased molecular weight can improve encapsulation efficiencies, particularly for 
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proteins, and produce structures with improved mechanical properties, such as 
macroscale implants.  Current polymerization protocols can routinely yield polymers on 
the order of 5 kDa.  The addition of reprecipitation steps reduces the yield but can 
increase molecular weight up to 10-12 kDa, but these molecular weights are still not 
comparable to degradable polyesters, which can be produced in commercial scale with 
molecular weights exceeding 100 kDa.  By increasing the molecular weight would allow 
for the use of polyketals as structural elements.  A potential project could consist of 
characterizing mechanical properties of polyketals and engineering different molecular 
architecture, such as branching, in order to improve molecular weight.  One important 
aspect of this project will be focusing on polymer solubility.  As polyketals increase in 
molecular weight, they may tend to become insoluble in common organic solvents.  One 
collaborative project that was attempted, but ultimately did not progress focused on 
electrospinning polyketals into nanoscale fibers that could be used for tissue engineering 
applications.  Electrospinning requires highly viscous and entangled solutions of 
polymers, which generally requires high molecular weight.  Even attempting to use an 
emulsion to electrospin, which has be previously shown to improve the electrospinning of 
low molecular weight polymers [155], did not yield fibrous structures.  Increased 
molecular weight polyketals or branched polyketals could be used to fabricate scaffolds 
to deliver cells and other bioactive factors to the heart as has been reported by other 
groups in the electrospinning literature [156]. 
6.2 Metal-Affinity Drug Delivery Systems 
 Chapter 4 describes a simple, yet effective, technique that can be used to 
functionalize the surface of polymer microparticles with NTA-Ni.  This functionality 
allows for the non-covalent tethering of any His-tag bearing protein, which can serve as a 
therapeutic payload or targeting ligand.  The primary benefit conferred by this technique 
is that proteins can be loaded without exposure to organic solvent, a potential 
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denaturation risk, and without any complicated chemical modifications, both of which 
could reduce protein bioactivity.  An added benefit is that any protein not tethered to the 
particle can be recovered by centrifuging the microparticles and collecting the 
supernatant.  This is particularly useful when working with expensive or difficult to 
express proteins.  Once tethered to the particle, bioactive protein can release from the 
particle and the non-covalent linkage is strong enough to achieve modest targeting to cell 
surface proteins in vitro. 
 While the paper published in Biomaterials [157] showed proof of principle for the 
concept, the NTA-Ni drug delivery system has yet to be applied to a MI model.  Given 
the rapid release kinetics seen in vitro, this system is suited for delivering a “one-two-
punch” consisting of a fast acting protein drug followed by sustained delivery of a longer 
acting small molecule.  To that end, mechanisms that mitigate the inflammatory response 
are being investigated.  One project involves modulating macrophage response by co-
delivering interleukin-4 (IL-4) and a small molecule anti-inflammatory (such as 
SB239063) in order to drive macrophages towards a less inflammatory M2 phenotype.  
The initial milieu of cytokines in a tissue can drive macrophages towards resolving or 
increasing inflammation in tissue [158].  Exogenous IL-4 has been shown to reduce the 
inflammatory response in myocarditis and improve cardiac function [159], and may have 
beneficial effects for treating cardiac dysfunction following MI. 
 One of the hurdles that this project may face is the lack of control of the release 
kinetics His-tagged protein.  The release half life of His-tagged GFP in vitro was 12 
hours, which may be too short for some therapeutic proteins.  The foundation for another 
project could lie in modulating the kinetics of protein release from NTA-Ni systems.  As 
mentioned in Chapter 2, the NTA-Ni/Histidine interaction can be modulated using a 
variety of factors.  One of the common ways to do this in the chromatography field is by 
changing the divalent metal ion; cobalt is routinely substituted for nickel and has higher 
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affinity.  While this is feasible, cobalt is more toxic and could lead to additional 
problems.  A more likely solution would be to synthesize a multivalent NTA moiety 
[160].  While the metal-histidine interaction strength would be the same, the apparently 
affinity would be stronger due to increased avidity.  Over the course of the project, two 
potential avenues for achieving this were identified.  The first involved synthesizing a 
trivalent NTA-lipid molecule, similar to the DOGS-NTA lipid described in Chapter 4.  
The second involved direct modification of poly(vinyl alcohol) (PVA).  PVA is routinely 
used as a surfactant to stabilize emulsions used to form microparticles.  Previous studies 
have shown that up to five weight percent of PVA is retained in the dry microparticle 
[161].  The PVA is arranged in a tennis-ball-fuzz-like morphology, with parts of a PVA 
chain embedding into the polymer core and other parts of the chain interacting with the 
water interface.  These pendant hydroxyl groups could be modified to contain NTA-Ni.  
In both cases, a His-tagged protein would have the same off rate from the NTA-Ni, but it 
would hop between metal complexes, increasing its residence time on the microparticle.  
An additional level of control could also be achieved by modulating the number of 
Histidine residues on the recombinant protein [58]. 
 While the data show that nickel loaded microparticles did not have any adverse 
effects on neonatal cardiac myocytes or RAW 264.7 macrophages, the general concern 
for nickel hypersensitivity, which has been hypothesized to underlie some adverse 
reactions to metal implants, may ultimately preclude NTA-Ni systems from being used in 
humans.  However, there is growing data in the chromatography literature examining 
binding affinities of less toxic ions, such as Zn(II) [162, 163], that may be better suited 
for drug delivery applications. 
6.3 Hoechst-Based Targeting of Extracellular DNA  
 Chapter 5 demonstrates that a variety of Hoechst-inspired compounds could be 
synthesized for the purpose of targeting extracellular DNA in necrotic tissue.  These 
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conjugates showed differential cell permeability in order to prevent binding to DNA in 
cell nuclei as well as different functionality for conjugation to other molecules.  Proof of 
principle for targeting necrotic extracellular DNA in the heart was demonstrated using a 
near infrared-Hoechst conjugate.  This compound was able to highlight the infarcted 
region of the heart from the surrounding tissue.  However, subsequent studies using 
Hoechst-conjugated VEGF did not show any enrichment in the left ventricle free wall as 
measured by ELISA.  Hoechst-conjugated SOD also failed to show enrichment in the 
infarcted area following intravenous injections, even at high doses, as measured through 
highly sensitive SOD activity assays.  While these attempts were unsuccessful, Hoechst-
conjugated molecules may still play a role in the cardiac field as a probe for necrosis in 
imaging as well as a targeting ligand for other disease models. 
 We are currently investigating the possibility of using Hoechst-diethylene 
triamine pentaacetic acid (Ho-DTPA) as a contrast agent for positron emission 
tomography (PET) or MRI.  Ho-DTPA can chelate metals such as gadolinium or copper-
64, which are commonly used in MRI and PET, respectively.  Late contrast gadolinium 
imaging is currently used today to determine the extent of necrosis following MI.  While 
this has been shown to be effective, the necrotic signal is highly dependent factors such 
as time after gadolinium administration and extent of occlusion in experimental models 
[164].  Development of necrosis-specific probes that are not dependent on hemodynamic 
properties of necrotic tissue may be more suitable for these purposes and for imaging 
silent infarctions or non-ST elevated MI.   
 Before these contrast agents can be used for these purposes, the kinetics of 
extracellular DNA in the heart must first be determined.  Previous studies relied on 
protein-based measures of necrosis; Kajstura, et al. and others have previously used a 
circulating antibody for myosin as a surrogate marker for necrosis [144, 148].  However, 
different components generated by necrotic cell death are likely cleared at different rates; 
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DNA clearance is expected to be much faster than protein components and thus would 
have a shorter window of opportunity to target extracellular DNA.  Commercially 
available DNA assays are not appropriate for measuring extracellular DNA as most of 
these dyes are cell permeable.  Radiolabeled Hoechst compounds could provide us with 
the kinetic data for DNA clearance and was proposed.  However, proper clearance to 
synthesize and use radioactive compounds was not obtained over the course of this 
project.  A more thorough understanding of how fast DNA is cleared from the infarct 
would allow for better assessment of the feasibility of using Hoechst-targeted 
therapeutics or contrast agents.  Ultimately, the future directions discussed hinge on a 
suitable window of opportunity for targeting the extracellular DNA. 
 One of the obvious applications for Hoechst-conjugates is in treating tumors.  
Tumor masses contain a necrotic core which persists due to insufficient vascularization.  
The Murthy laboratory has applied Hoechst technology to the chemotherapeutic 
gemcitabine.  This strategy has an advantage in that it is autocatalytic; small amounts of 
the Hoechst-gemcitabine localizing in the tumor will actually generate more extracellular 
DNA.  Subsequent doses of the chemotherapeutic then have a larger platform to target, 
which in turn kills additional cells.  Early results for this therapy are promising and 
manuscripts have been submitted for review. 
 However, in the cardiovascular arena, the greatest chance for success with 
Hoechst-targeted therapeutics likely lies in small molecule conjugates.  Given that 
diffusivity is proportional to the mass of a given species, small molecule conjugates have 
a greater chance of escaping the capillary beds and diffusing deep into to the necrotic 
tissue were it can bind to extracellular DNA.  This effect would be significantly more 
pronounced in large animal models of MI compared to rodents.  Potential projects could 
focus on the synthesis and testing of Hoechst-TEMPOL or Hoechst-ebselen, commonly 
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used small molecule mimetics of SOD and catalase, respectively.  Alternatively, 
cleavable linkers could be used to deliver small molecule inhibitors. 
 Another strategy that may prove successful for Hoechst-based targeting is to 
decorate the surface of a delivery vehicle with the ligand.  This would have the beneficial 
effect of increasing the avidity and improve binding properties.  This strategy has been 
frequently used with liposomal formulations and antibody targeting ligands.  However, 
the size of the delivery vehicle will likely play a large role, as a balance must be found 
between the binding force between Hoechst and DNA and the convective drag force 
between the delivery vehicle and blood/lymphatic flow. 
6.4 Perspective 
 Materials development is still in the process of catching up to the biological 
demands of in vivo applications.  Most of the materials used in medicine today were 
selected on the basis of availability and mechanical suitability based on what clinicians 
had on hand.  A famous example highlights the fact that researchers at the NIH were 
inspired by the elasticity and durability of a woman’s girdle, which eventually led to the 
use of the same material, poly(ether urethane), in the first artificial heart [165].  While 
these approaches have produced large advancements in the field of medicine, the need for 
specifically designed chemistries for biological applications is becoming increasingly 
evident.  However, this type of research requires a multidisciplinary approach that 
requires teams to start with rational design of molecules, progress to synthesis, and 
eventually test these compounds in vivo.  This dissertation was an attempt to achieve this 






A.1 Polyketal synthesis 
 Poly(cyclohexane-1,4-diyl acetone dimethylene ketal) (PCADK) was synthesized 
as described in Lee, et al (2007) [125].  Briefly, 1,4-cyclohexanedimethanol was reacted 
with 2,2-dimethoxypropane in an acetal exchange reaction.  First, 1,4-cyclohexane 
dimethanol was dissolved in benzene and brought to 100°C with constant stirring.  A 
solution of p-toluenesulfonic acid in ethyl acetate was added to the reaction flask in order 
to catalyze the reaction.  The ethyl acetate was allowed to boil off, and distilled 2,2-
dimethoxypropane was added to the benzene solution in an equimolar ratio to 1,4-
cyclohexanedimethanol, initiating the polymerization reaction.  Additional doses of 2,2-
dimethoxypropane and benzene were subsequently added to the reaction dropwise to the 
reaction flask via a metering funnel to compensate for the 2,2-dimethoxypropane and 
benzene that had been distilled off.  After 8 hours, the reaction was stopped by addition 
of 500 μL of triethylamine.  The polymer was isolated by precipitation in cold hexane 
(stored at -20°C) followed by vacuum filtration.  The molecular weight of the resulting 
polymer was approximately 6 kDa with a mean polydispersity of 1.923.  All reagents 
were purchased from Sigma-Aldrich.  2,2-dimethoxypropane and benzene were distilled 
prior to use.  p-Toluenesulfonic acid was recrystallized prior to use.  All other reagents 




A.2 Microparticle formulation 
SB239063-loaded microparticles 
 Polyketal particles loaded with SB239063 (Axxora) (PK-p38i) were generated 
using an emulsion-solvent evaporation technique.  Five-hundred micrograms of inhibitor 
and 50 mg of PCADK were dissolved in 500 μl of dichloromethane.  The polymer 
solution was then added to 5 mL of 4% poly(vinyl alcohol) (PVA) and homogenized at a 
low speed for 60s.  The resulting emulsion was transferred to 30 mL of 1% PVA and 
stirred at approximately 100 rpm for 4h to allow for evaporation of dichloromethane and 
solidification of microparticles.  The particles were then centrifuged and washed in 
deionized water three times to remove residual PVA.  The suspension was then frozen in 
liquid nitrogen and lyophilized to produce a free flowing powder.   
 PLGA (Resomer RG 503 H, 48:52 lactide:glycolide, 0.32-0.44 i.v., Boehringer 
Ingelheim) was used as received.  Microparticles containing SB239063 were made with 
the same protocol for PCADK particles. 
NTA modified PCADK microparticles 
 PCADK was synthesized as described above.  NTA-bearing microparticles were 
made in 100 mg batches via a single emulsion procedure.  1,2-dioleoyl-sn-glycero-3-[(N-
(5-amino-1-carboxypentyl)iminodiacetic acid)succinyl] (DOGS-NTA, Avanti Polar 
Lipids) was dissolved in dichloromethane at 10 mg/ml.  The following procedure was 
used to produce 10 wt% NTA microparticles; other concentrations were obtained by 
varying the amount of DOGS-NTA stock solution and neat dichloromethane.  Ninety 
milligrams of PCADK was added to 1 ml of DOGS-NTA stock solution and gently 
heated to dissolve the polymer.  Five milliliters of 4% PVA in water was added to the 
polymer solution and the mixture was homogenized using a Powergen 500 
(ThermoFisher) homogenizer for 60 seconds.  The resulting emulsion was transferred to 
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30 ml of 1% PVA and stirred for 4-6 h to evaporate the dichloromethane.  Particles were 
then centrifuged and washed with deionized water before being frozen in liquid nitrogen 
and lyophilized to produce a free flowing powder.  Microparticles were subsequently 
loaded with Ni
+2
 by incubating overnight in a 0.05 M NiCl2 solution at a concentration of 
1 mg particles/ml. 
 
A.3 Synthesis of Hoechst compounds 
Hoechst-amine and Ho-IR786 synthesis 
Hoechst amine was synthesized according to the schemes in Figures A.1-A.3.  Detailed 
experimental procedures and characterization of Hoechst-amine and Hoechst-IR786 were 
described by Dasari, et al [145]. 
 














































Figure A.2. Synthetic scheme for ethyl 4-(2-(2-(2-(1,3-dioxoisoindolin-2-yl)ethoxy)ethoxy)ethoxy) 
benziminium salt (16). 
 


































































Hoechst-biotin and Hoechst-maleimide were synthesized from Hoechst-amine using 
NHS-coupling chemistry.  EZ-link NHS-PEG12-Biotin and NHS-PEG4-Maleimide were 
purchased form Thermo/Pierce.  Twenty-five milligrams of Hoechst-amine was dissolved 
in 5 ml of anhydrous dimethy formamide (DMF) with 20 equivalents of triethyl amine 
under nitrogen).  One equivalent of NHS-PEG compound was added to the reaction 
mixture and stirred overnight.  Progress was monitored using TLC (MeOH:DCM).  Upon 
completion of the reaction, DMF was removed under reduced pressure and the reaction 
mixture dissolved in 20% MeOH in DCM with 0.5% triethylamine.  This mixture was 
streaked on preparative TLC plates and developed using 10% MeOH in DCM with 0.5% 










Figure A.5. Hoechst-maleimide mass spectrum. 
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VEGF was expressed with unpaired cysteine residues as described by Phelps, et al [146].  
Protein was provided at 140-280 µg/ml and were dialyzed against PBS (adjusted to pH 8 
with 2 mM EDTA) for 24 hours at 4°C.  Ten equivalents of Hoechst-maleimide were 
added to the VEGF and reacted overnight at 4°C.  The reaction mixture was then dialyzed 
(MWCO 3500 Da) against PBS overnight at 4°C to remove any unreacted Hoechst-
maleimide.  Aliquots of the protein were made and stored at -20°C. 
 
Figure A.6. Synthesis scheme for HoVEGF. 
 
Superoxide dismutase (from Bovine erythrocytes, ≥3000 U/mg, Sigma-Aldrich) was 
dissolved at 10 mg/ml in PBS adjusted to pH 8 with 2 mM EDTA.  SOD was assumed to 
have 20 primary amines, subsequent equivalents were calculated based on this 
assumption.  Traut’s reagent (Sigma-Aldrich) was added in a 20 equivalent excess and 
allowed to react for one hour at room temperature.  Unreacted Traut’s reagent was 
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separated from thiolated-SOD (SOD-SH) using a polyacrylamide desalting column 
(MWCO 6000 Da, Thermo/Pierce) run with PBS adjusted to pH 8 with 2 mM EDTA.  
Two-hundred microliter fractions were collected in a UV 96-well plate and UV spectra 
taken for each well to determine fractions that contained SOD.  Protein concentration 
(µBCA assay, Thermo/Pierce), SOD activity (SOD Activity Kit – WST, Dojindo 
Molecular Technologies), and sulfhydryl content (Ellman’s Assay, Thermo/Pierce) of the 
pooled SOD-SH fractions were assessed according to manufacturers’ protocols.  SOD-
SH was then reacted with Hoechst-Maleimide (2 equivalents with respect to –SH).  The 
reaction mixture was again purified using a polyacrylamide size exclusion column as 
described above.  Modified protein was validated using MALDI-TOF as described 
previously.  Protein concentration was increased using centrifuge-based Pierce Protein 
Concentrators (9MWCO 9000 Da, Thermo/Pierce) as needed. 
 
 




A.4 Cell culture 
 RAW264.7 macrophages were maintained in DMEM (Fisher) supplemented with 
10% fetal bovine serum (Hyclone), l-glutamine, and penicillin/streptomycin (Invitrogen).  
For experiments involving TNF-α stimulation, cells were plated at confluence 18 hours 
prior to experiments in serum free media (SFM, DMEM supplemented with l-glutamine 
and penicillin/streptomycin).  Media was then aspirated and replaced with treatment 
media containing either SB239063 dissolved in DMSO, neat DMSO as a control, or 
polyketal microparticles.  Cells were preincubated with the treatment for the indicated 
time and washed with fresh SFM media before being exposed to 10 ng/mL TNF-α 
(Sigma). 
 Human umbilical vein endothelial cells (HUVEC) were maintained in M199 
media (Hyclone) supplemented with 20% fetal bovine serum (FBS, Hyclone), 
penicillin/streptomycin/l-glutamine (Gibco), heparin (20 U/ml, BD biosciences), and 
endothelial cell growth supplement (BD Biosciences).  Cells were passaged with 
trypsin/EDTA at 80-90% confluence.  Tissue culture flasks were coated with a 1 mg/ml 
solution of gelatin for 20 min at room temperature before plating cells. 
 Rat neonatal cardiac myocytes were obtained from 1-2 day old Sprague-Dawley 
pups (Charles River Labs).  Pups were sacrificed and ventricles isolated and minced.  The 
tissue was minced and suspended in a 1 mg/ml solution of collagenase (Worthington) in 
Hank’s buffered saline solution (HBSS) for 4-6 h at 4°C.  The suspension was filtered 
through a 70 μm screen and centrifuged 10 min at 500g.  The supernatant was discarded 
and pellet resuspended and washed in Hanks’ buffered saline solution (HBSS ) three 
times before being plated in DMEM supplemented with 10% FBS.  Tissue culture flasks 
were treated with a 1 μg/ml solution of fibronectin before cells were plated. 
 Prior to all experiments, cells were quiesced overnight in serum-free media.  All 
cells were incubated at 37°C with 5% CO2 and 100% humidity. 
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A.5 Bioplex cytokine analysis and inflammation studies   
 C57BL6 adult mice (Charles River) were anesthetized under isofluorane (1-3%, 
Charles River).  Thighs were shaved and skin was incised to expose the muscle.  For 
cytokine measurements, muscle was injected with 1 mg of polymer (100 μl of 10 mg/mL 
solution in sterile saline).  The contralateral leg was injected with saline as a control.  For 
immunohistochemical analysis 5 mg (100 μl of 10 mg/mL solution in sterile saline) was 
injected into the muscle.  At the designated intervals, mice were sacrificed by CO2 and 
the leg muscles exposed.  Approximately 50 mg of muscle was removed at the injection 
site and processed. 
 For cytokine analysis, tissue was frozen in liquid nitrogen and homogenized in 
Cell Lysis Buffer (Bio-Rad) according to manufacturer’s instructions.  Briefly, tissue was 
homogenized in 0.5 mL of lysis buffer and sonicated to ensure full disruption of tissue.  
The homogenate was centrifuged and supernatant incubated with X-Plex multiplex beads 
(Bio-Rad) according to manufacturer’s instructions and analyzed on a Bio-Rad Bioplex 
system. 
A.5 Histological analysis 
 For immunohistochemical analysis, tissue was fixed in 4% paraformaldehyde 
(Sigma) and embedded in paraffin.  Histological sections were made and stained with 
anti-CD-45 antibody using standard immunohistochemical techniques.  DAPI was used 
to visualize nuclei in the sections.  Slides were imaged under fluorescence microscopy 
and digital images of the sections saved. 
 Collagen deposition was determined by Picrosirius Red (Sigma) staining as 





A.6 Western blot analysis  
p38 MAPK Western Blots 
 Cell (250 µg) or tissue (500 µg) protein homogenates were incubated with an 
antibody against total p38 (Cell Signaling) overnight at 4°C, prior to 2 hour incubation 
with Protein-A agarose beads (Sigma).  Beads were washed and boiled in sample buffer 
prior to loading on a 12% polyacrylamide-SDS gel.  Proteins were transferred to a PVDF 
membrane (Bio-Rad) and blots probed with an antibody for phospho-specific p38 (Cell 
Signaling).  Films were scanned and quantified using Image J software. 
A.7 Quantification of superoxide via DHE-HPLC   
To determine levels of superoxide in cells and tissues, a novel method described recently 
was used.  Dihydroethidium (DHE) is a commonly used immunohistochemical marker to 
measure superoxide in tissues.  However, when DHE is oxidized by superoxide, it 
becomes impermeable to cells.  Therefore, any DHE oxidized in the extracellular space 
will remain in the incubation medium.  This oxidation product, 2-hydroxyethidium, has a 
different retention that ethidium and can be quantified by high performance liquid 
chromatography (HPLC) with fluorescence detection [167]. 
 To detect tissue superoxide following myocardial infarction in rats, the left 
ventricular free wall was harvested at the indicated time point and equal sized pieces 
were incubated at 37°C in 1 mL of Krebs/Hepes buffer (KHB; pH= 7.35) containing 50 
µM dihydroethidium (Invitrogen) for 30 minutes.  Following incubation, buffer was 
syringe filtered and 100 µL placed in a tube containing 300 µL methanol.  The sample 
was loaded on a C18 column for reverse-phase HPLC anaylsis using an acetonitrile 
gradient and data were normalized to wet tissue weight.   
 For cell culture experiments, macrophages were incubated with polyketals for the 
indicated time period.  Following polyketal pre-treatment, cells were incubated with 10 
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ng/mL TNF-α for 5 minutes in KHB at 37°C, prior to addition of 25 µM dihydroethidium 
for 20 minutes.  Buffer was collected and analyzed in a manner similar to tissue studies. 
TNF-α measurement.  Protein homogenates were evaluated for TNF-α levels by ELISA 
(eBiosciences) according to manufacturer’s protocol and normalized to protein levels 
determined by Bradford assay. 
 
 
A.8 NTA-Ni microparticle characterization 
GFP quantification 
 Green fluorescent protein (GFP) bearing a His-tag was obtained from Millipore.  
Microparticles were loaded with GFP by incubating them in GFP solutions made with 
phosphate buffered saline (PBS) at a concentration of 1 mg particles/ml overnight at 4°C.  
Particles were centrifuged and washed three times with PBS.  Following washing, 
microparticles were incubated with a horseradish peroxidase-conjugated antibody against 
GFP (1:5000 dilution in PBS-T with 1% goat serum, Rockland) for 2 h at 4°C.  Particles 
were again washed with PBS three times and resuspended in PBS at a concentration of 1 
mg particles/ml.  Five microliters of the particle suspension were aliquotted into wells of 
a 96-well plate and amounts of GFP quantified colorimetrically via tetramentylbenzidine 
(1-Step Slow TMB, Pierce) conversion in a plate reader (Biotek Synergy 2).  Kinetic 
reads were compared to standard curves and supernatants that have been immobilized on 
HisGrab 96-well plates (Pierce). 
Release studies 
 Microparticles containing 2 wt% rhodamine-B (TCI Chemicals) and 10 wt% NTA 
were made using a modification to the above procedure.  Microparticles were loaded in a 
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1 μg/ml solution of GFP overnight at 4°C.  After washing, microparticles were suspended 
at 1 mg/ml in PBS and aliquotted into separate samples.  The release study was 
conducted at 37°C.  At specified time points, particles were centrifuged, supernatant 
collected for analysis, and fresh buffer used to resuspend the particles.  GFP was 
quantified via ELISA and rhodamine-B via fluorescence measurements.  Total 
rhodamine-B was measured by hydrolyzing the particles in 1 N HCl and measuring 
fluorescence.  SB239063 release data was obtained from Sy et al. (35) 
MTT assay 
 Cells were plated at confluence in 6 well plates and quiesced with serum-free 
media overnight.  Cells were then washed with PBS and treated with microparticles 
suspended in serum free media (1 ml per well) for 6 h.  3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyl tetrazolium bromide (MTT) was dissolved in phenol red-free DMEM at a 
concentration of 0.5 mg/ml. Following microparticle treatment, cells were washed three 
times with PBS to remove microparticles and incubated with MTT media for 2h.  Cells 
were then washed three times with PBS and 0.5 ml of MTT solvent (0.1 N HCl in 
isopropanol) was added to each well to dissolve formazan crystals.  This solution was 
centrifuged to pellet cell debris and measured spectrophotometrically at 570 nm. 
VEGF studies and Western Blotting 
 His-tagged VEGF (His-VEGF) was expressed as described in (36).  HUVECs 
were plated on gelatin coated 6 well plates at confluence and quiesced overnight in 
serum-free media.  Ten percent NTA microparticles were loaded with nickel as described 
above, washed, and incubated with a solution of 1 μg His-VEGF/ml in PBS overnight at 
4°C.  The microparticles were then washed three times with PBS and resuspended in a 
serum-free media at various concentrations.  One milliliter of media with microparticles 
was added to each well and incubated at 37°C for 20 minutes.  Controls of NTA-Ni 
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microparticles (no His-VEGF) and free VEGF (0-100 ng/ml) were also tested.  Following 
incubation, cells were washed three times with ice cold PBS with phosphatase inhibitors 
(Sigma).  Protein was harvested in 75 μl of ice cold RIPA buffer with protease and 
phosphatase inhibitors (Sigma).  Lysates were centrifuged to pellet cell debris and 
microBCA assays (Pierce) were used to determine protein concentrations for each 
sample.  Protein lysates were run under denaturing conditions (Laemmli Buffer system) 
on 7% polyacrylamide gels and transferred to PVDF membranes.  Membranes were 
blocked and probed for phospho- and total- VEGFR2 antibodies (Cell Signaling) using 
manufacturer protocols.  Band intensities were determined by exposing films using a 
HRP-ECL (Amersham) system. 
Cell targeting studies 
 HUVECs were plated on gelatin-coated coverslips at 30% confluence and 
quiesced overnight in serum-free media.  Ten percent NTA-microparticles with 1% 
coumarin-6 or rhodamine-B were loaded with nickel as described above, washed three 
times and incubated with a 100 nM solution of rhVE-Cadherin (R&D Systems) and 2 
mM CaCl2 overnight.  Particles were then washed and suspended in serum-free media at 
a concentration of 0.1 mg microparticle/ml.  Cells were washed once with PBS and 
incubated with microparticles for 3h at 37°C.  Following incubation, media was aspirated 
and washed once with PBS, followed by a 30-min incubation with 4% paraformaldehyde 
in PBS at room temperature.  Cells were then rinsed three times with PBS+0.1% BSA 







A.9 Animal studies 
Rat Myocardial Infarction Model  
 Adult male Sprague-Dawley rats (obtained from Charles River) weighing 250 
grams were subjected to myocardial infarction/injection surgeries in a randomized and 
double-blinded manner.  Briefly, the animals were anesthetized (1-3% isoflurane 
(Webster Veterinary) and, following tracheal intubation, the heart was exposed by 
separation of the ribs.  Myocardial infarction was performed by ligation of the left 
anterior descending coronary artery.  For PK injection or cell therapy studies, 
immediately after coronary artery ligation, polyketals (50 µL) were injected into the 
infarct zone through a 30-gauge needle while the heart was beating.  Following injection, 
the chests were closed and animals allowed to recover on a heating pad.  At the indicated 
time points, magnetic resonance imaging (MRI) was performed and data analyzed in a 
blinded manner.  For immunohistological evaluation, hearts were harvested and fixed in 
4% paraformaldehyde.  Following dehydration, hearts were embedded in paraffin and 5 
µm sections were made. 
Mouse Ischemia-Reperfusion Surgery 
 C57/Bl6 mice, 8-12 weeks old, were anesthetized (1-3% isoflurane) and 
intubuated.  The heart was exposed by separation of the ribs and the LAD ligated for 
thirty minutes.  Following thirty minutes of occlusion, the suture was release and chest 
sutured. 
In Vivo Imaging of Myocardial Infarction  
 IR-surgery was performed as described above.  After 2 h, 10 nmol of Hoechst-IR 
in 0.1 mL saline, supplemented with 5% ethanol and 5% cremophor EL (PEG-
functionalized castor oil), was injected intravenously via retro-orbital injection.  The 
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compound was allowed to circulate for 1 h before the animals were sacrificed and 
perfused for 5 min with saline and 5 min with 4% paraformaldehyde in PBS buffer.  
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